Conditions: Peripheral Arterial Disease
Keywords: peripheral arterial disease granulocyte macrophage colony stimulating factor PAD GM-CSF sargramostim leukine treadmill exercise
Allocation: RANDOMIZED | Intervention model: FACTORIAL
Enrollment: 210
Healthy volunteers: no

Brief summary:
The PROPEL study will test the hypothesis that GM-CSF combined with supervised treadmill exercise will significantly improve functional performance in patients with PAD more than GM-CSF alone or supervised treadmill exercise alone. In addition to identifying novel therapeutic options for patients with PAD, the current proposal is expected to identify mechanisms by which functional impairment is improved in patients with PAD.

Detailed description:
Eight million men and women in the United States have lower extremity peripheral arterial disease (PAD). PAD is expected to be increasingly common as the population survives longer with chronic disease. Patients with PAD have greater functional impairment and faster functional decline compared to those without PAD. However, currently there are only two FDA approved medications for improving functional performance in patients with PAD. Furthermore, these FDA approved medications are only modestly beneficial for improving walking performance in patients with PAD.

Preliminary evidence suggests that increasing circulating levels of CD34+ cells with granulocyte macrophage colony stimulating factor (GM-CSF) or other therapies may improve walking performance in patients with PAD. However, results of small clinical trials testing the ability of GM-CSF to improve walking performance in patients with PAD are mixed. The association of GM-CSF with improved walking performance in PAD is not definitively established. Preliminary data also suggest that lower extremity ischemia, induced during walking exercise, may increase circulating CD34+ cell levels, enhance homing of CD34+ cells to ischemic sites, and augment the ability of GMCSF to improve walking performance in PAD. However, it is currently unknown whether the combination of GM-CSF and supervised treadmill exercise significantly improve functional performance more than either therapy alone.

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None

Interventions: intervention 1: Supervised Treadmill Exercise Therapy intervention 2: Health education sessions (Control) intervention 3: granulocyte macrophage colony stimulating factor (GM-CSF)
Intervention descriptions: intervention 1: Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade. intervention 2: Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise. intervention 3: The dose of GM-CSF will be 250 ug/M\^2 subcutaneously three times weekly for two weeks.

Protocol document:
Prot_SAP_000.pdf: 
Version 3.13.2017
1
PROgenitor cell release Plus Exercise to improve functional performance in PAD:
The PROPEL Study
Principal Investigator: Mary McDermott, MD
SPECIFIC AIMS
Preliminary evidence suggests that increasing circulating levels of CD34+ cells with granulocyte monocyte 
colony stimulating factor (GM-CSF) or other therapies may improve walking performance in patients with lower 
extremity peripheral arterial disease (PAD) (1,2).  However, results of small clinical trials are mixed (1-4). The 
association of GM-CSF with improved walking performance in PAD is not definitively established.  Preliminary 
data also suggest that lower extremity ischemia, induced during walking exercise, may increase circulating 
CD34+ cell levels, enhance homing of CD34+ cells to ischemic sites, and augment the ability of GM-CSF to 
improve walking performance in PAD (1,2).  We propose a randomized controlled clinical trial (2 x 2 factorial 
design) of 240 participants with PAD randomized to one of four arms:  Group A: GM-CSF + supervised 
exercise therapy; Group B: GM-CSF therapy + an attention control group; Group C: placebo + supervised 
exercise therapy; and Group D: placebo + attention control group.  Our primary outcome is change in six-
minute walk performance between baseline and 12-week follow-up.  From this point forward, “GM-CSF 
combined with supervised treadmill exercise” refers to Group A; “GM-CSF therapy alone” refers to Group B, 
“supervised exercise therapy alone” refers to Group C, and no active therapy refers to Group D.
Primary Specific Aim.  
1.  We will determine whether GM-CSF combined with supervised treadmill exercise (Group A) achieves  
greater improvement in six-minute walk performance at 12-week follow-up, compared to GM-CSF alone 
(Group B) and supervised exercise alone (Group C), respectively.  We hypothesize that PAD participants 
randomized to Group A will achieve greater improvement in six-minute walk performance at 12-week follow-up, 
compared to those randomized to Group B and those randomized to Group C, respectively.  
2. We will determine whether GM-CSF therapy alone (Group B) significantly improves six-minute walk 
performance at 12-week follow-up, compared to Group D.  We hypothesize that PAD participants randomized 
to Group B will achieve greater improvement in the six-minute walk at 12-week follow-up than Group D.
3.  We will confirm that supervised treadmill exercise therapy alone (Group C) significantly increases six-
minute walk performance at 12-week follow-up, compared to Group D. We hypothesize that PAD participants 
randomized to Group C will achieve greater improvement in six-minute walk performance at 12-week follow-up, 
compared to those randomized to Group D.   
Secondary Specific Aim.  
1.  We will determine whether GM-CSF combined with supervised exercise (Group A) is associated with 
greater increases in brachial artery flow-mediated dilation (FMD) and maximal treadmill walking time at 12-
week follow-up, compared to GM-CSF alone (Group B) and supervised exercise alone (Group C), respectively.  
2.  We will determine whether GM-CSF alone (Group B) is associated with significantly greater increases in 
brachial artery FMD and maximal treadmill walking time at 12-week follow-up, compared to Group D.  
3.  We will determine whether a supervised treadmill exercise intervention alone (Group C) is associated with 
greater increases in CD34+ cells at 12-week follow-up, compared to Group D.  
4.  We will confirm prior data demonstrating that supervised treadmill exercise alone (Group C) is associated 
with greater increases in brachial artery FMD and maximal treadmill walking time, compared to Group D. 
In our Exploratory Aim, we will establish the temporal trajectory of favorable changes in study outcomes in 
response to GM-CSF.  “Study outcomes” refers to six-minute walk performance, maximal treadmill walking 
time, and brachial artery FMD.  We will also establish the temporal trajectory of increases in progenitor cells in 
response to supervised treadmill exercise.  We will determine whether the degree of increase in progenitor 
cells is associated with the degree of improvement in study outcomes.  
Exploratory Specific Aims.  
1.  We will determine whether GM-CSF combined with supervised treadmill exercise therapy (Group A) is 
associated with greater increases in study outcomes at six-week follow-up and at six-month follow-up, 
compared to GM-CSF therapy alone (Group B) and supervised exercise therapy alone (Group C), respectively.  
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
2
2.  We will determine whether GM-CSF alone (Group B) is associated with greater increases in study 
outcomes at six-week follow-up and at six-month follow-up, respectively, compared to Group D.  
3.  We will determine whether supervised exercise therapy alone (Group C) is associated with significantly 
greater increases in CD34+ cells and other progenitor cell measures at two-week follow-up, six-week follow-up 
and at six-month follow-up, compared to Group D.  
4.  Among participants receiving GM-CSF, we will determine whether the degree of increase in progenitor cell 
measures at two-week follow-up is associated with the degree of improvement in remaining study outcomes at 
six-week, 12-week, and six-month follow-up, respectively.  
5.  Among up to 30 participants with PAD and 15 consenting participants who are determined not to have PAD, 
we will determine whether progenitor cell measures increase acutely after a treadmill exercise stress test 
among participants with PAD and among those without PAD, respectively.  We will further determine whether 
greater increases in progenitor cell measures after a treadmill exercise stress test are associated with better 
six-minute walk performance and higher ABI values at baseline, compared to lesser increases in progenitor 
cell measures after a treadmill exercise stress test.
6. Study participants will have the option of participating in a sub study that consists of a muscle biopsy of the 
medial head of the gastrocnemius muscle.  The muscle biopsy will be performed by Dr. Robert Sufit, a board 
certified neurologist with more than 20 years of experience performing lower extremity muscle biopsies.  The 
muscle biopsy will be performed in a clinical examination room using an open biopsy technique.  A 
subcutaneous injection of lidocaine will be administered.  For the lower extremity biopsy, an incision will be 
made in the lower extremity muscle (medial head of the gastrocnemius muscle and approximately 250 mgs of 
muscle tissue will be removed.  Most or all of the sample will be frozen immediately in liquid nitrogen and 
stored at -80 degrees Celsius.  Participants will be asked to return for a follow-up visit to check the site of the 
muscle biopsy approximately one week after the procedure.    Participants may be asked to undergo a muscle 
biopsy at baseline and after 26-week follow-up.  Thus, the total number of muscle biopsies a participant may 
be asked to have is two (one lower extremity biopsy at baseline and one at six-month follow-up). We may take 
photographs of the biopsy site and biopsy tissue before, during, and after the procedure. We may take 
photographs at the post-biopsy incision check-up as well to show the scar and healing. These images will not 
show any identifying information such as name or date of birth. These images may be used for grant 
proposals, manuscripts, or other research related activities. Muscle specimens will be sent to the Universities 
of Florida and Kentucky for analyses that include inflammatory biomarkers, markers of oxidative stress, 
measures of mitochondrial function and quantity, and muscle myofiber typing. Analyses may also be tested for 
protein measures of mitochondrial function, macrophages, satellite cells, and PCR/gene expression. Other 
measures related to skeletal muscle quality and function may also be performed.
In addition, in a subset of participants we will obtain a muscle biopsy from the left and the right leg, 
respectively.  These bilateral biopsies could be obtained at baseline, at 26-week follow-up, or at both time 
points.  The second (contralateral) biopsy will be performed at least six days after the first biopsy.  In some 
cases, the second biopsy may take place when the participant returns for their incision site check after the first 
biopsy.  It will be necessary for these individuals to remain off of their anti-platelet therapy for 7 days before 
each procedure (i.e. potentially for approximately 14 days continuously). Physician approval will be required.  
A. RESEARCH STRATEGY- SIGNIFICANCE  
A1.  Lower extremity peripheral arterial disease (PAD) is common and is associated with functional 
impairment and functional decline.   PAD affects eight million men and women in the United States, and will 
be increasingly prevalent as the U.S. population survives longer with chronic disease (5).  Our work and that of 
others demonstrates that men and women with PAD have greater functional impairment and more rapid 
functional decline than those without PAD (6-10).  The functional impairments documented in PAD are 
associated with loss of independence, increased mortality, and poor quality of life (11-13).
A2.  Few medical therapies have been identified that improve functional impairment in PAD.  Only two 
medications, pentoxifylline and cilostazol, are FDA-approved for treating PAD-associated walking impairment.  
Of these, pentoxifylline is usually ineffective and benefits from cilostazol are modest (14-17).  New therapies 
are urgently needed to improve walking performance and prevent functional decline in patients with PAD.  
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
3
A3. Interventions that increase circulating progenitor cells are among the most promising emerging 
therapies for patients with cardiovascular disease. Progenitor cells normally exist in low concentrations in 
peripheral blood.  Interventions, such as GM-CSF, promote release of progenitor cells from bone marrow, 
spleen, and other sources into the circulation (18-20).  These circulating progenitor cells can differentiate into 
mature endothelial cells and form new blood vessels, termed neoangiogenesis (21-24).  In 1997, Asahara and 
colleagues demonstrated that CD34+ progenitor cells isolated from human peripheral blood differentiate into 
mature endothelial cells in vitro (22).  In a rabbit hind limb ischemia model, these isolated CD34+ cells 
migrated to sites of tissue ischemia and incorporated into developing blood vessels (22).  This work 
established that circulating progenitor cells isolated from humans can differentiate into mature endothelial cells 
and promote new blood vessel development in vivo.  Progenitor cells also repair endothelial-cell injury and are 
associated with improved endothelial function (21-30). Mobilizing EPC reserves may improve walking 
performance in patients with PAD by increasing calf muscle perfusion through angiogenesis and by improving 
endothelial function and cardiovascular health.  However, whether interventions that increase circulating 
progenitor cell levels improve functional performance in patients with PAD is not established.  
A4. Therapeutic potential of CD34+ progenitor cells.  The CD34+ cell marker clearly identifies functional 
progenitor cell populations that are released from bone marrow in response to tissue ischemia, differentiate 
into endothelial cells, and promote angiogenesis in vitro and in vivo (22,31,32).  In addition to the work by 
Asahara and colleagues described in section A3 (22), Ishida and colleagues harvested CD34+ cells from 
peripheral blood and injected them into calf muscle of six patients with peripheral ischemia (five with 
thromboangiitis obliterans and one with critical limb ischemia).  At six-week follow-up, participants experienced 
a 200% increase in treadmill walking distance (32).  However, the sample size was small and did not include a 
control group.  It is currently not established whether interventions that increase circulating levels of CD34+ 
cells can improve functional performance in patients with PAD.  
A5. Preliminary evidence suggests that GM-CSF may improve walking performance in people with PAD 
by increasing CD34+ cells.  Subcutaneous GM-CSF injections increase levels of circulating CD34+ cells by 
disrupting progenitor cell anchors in the bone marrow (33).  In hind-limb ischemia animal models, increasing 
circulating levels of progenitor cells is associated with calf muscle capillary formation, improved calf muscle 
perfusion, and increased exercise capacity (22,31,32).  However, three prior small clinical trials testing the 
ability of GM-CSF (or G-CSF) to improve walking performance in patients with PAD have shown mixed results 
(1,3,4).  Of these three randomized controlled clinical trials (summarized in Table 1), one demonstrated 
improved maximal walking distance (1) and one demonstrated no change in treadmill walking performance in 
response to GM-CSF (3).  While the third study demonstrated improved pain-free treadmill walking distance, 
the validity of this finding is questionable, since only four participants completed follow-up treadmill testing (4).  
Additional limitations of these studies follow.  First, sample sizes were small.  Second, generalizability of the 
findings to the typical patient with PAD is limited.  Participants in the study by Arai and colleagues all had 
critical limb ischemia (4), those in the study by Van Royan and colleagues all had maximal walking distances < 
200 meters (3), and those in the study by Subramaniyam and colleagues all had intermittent claudication (1).  
Yet most PAD participants will never have critical limb ischemia, many can walk > 200 meters on the treadmill, 
and most do not have symptoms of intermittent claudication (6,8,34,35).  Third, no study assessed whether 
episodes of lower extremity ischemia, induced during supervised treadmill exercise, increases responsiveness 
to GM-CSF.  Fourth, temporal trends in walking outcomes in response to the intervention were not evaluated in 
any study.  The length of time required to achieve maximal benefit from GM-CSF and the duration of any 
therapeutic benefit is unknown.  In summary, whether GM-CSF (or G-CSF) improves treadmill walking 
performance, with or without supervised treadmill exercise, remains unknown.  A definitive trial is needed.  
Table 1.  Summary of Prior Small Clinical Trials Studying the Ability of G-CSF or GM-CSF Therapy to 
Improve Walking Performance in PAD 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
4
Study
Participants 
Intervention(s)
Outcome 
Measure
Results
Study Limitations
Van Royen N 
et al (2005) (3)
40 with PAD 
and intermittent 
claudication 
(IC) who 
walked < 200 
meters on the 
treadmill. 
GM-CSF vs. 
placebo injections 
over 14 days.   
Maximal 
treadmill 
walking time at 
12-week follow-
up.
No difference between 
the intervention vs. 
control group in 
increasing treadmill 
walking performance.
1. Small sample size. 
2. Limited to PAD 
participants with IC 
and short maximal 
walking distance.  3. 
No supervised 
exercise therapy.
Arai M et al 
(2006) (4)
39 participants 
with PAD and 
critical leg 
ischemia.
G-CSF for 10 days 
(N=14) vs. bone 
marrow transplant 
and calf injection 
of mononuclear 
cells (N=13) vs. 
usual care (N=12).
Treadmill pain-
free walking 
time, ABI, and 
transcutaneous 
oxygen 
saturation at 4-
week follow-up.
G-CSF and bone 
marrow transplant 
were each associated 
with greater 
improvement in each  
outcome compared to 
usual care.
1. Small sample size.  
2. Limited to 
participants with 
critical limb ischemia.  
3. Only 4 participants 
completed treadmill 
test at follow-up. 
Subramaniya
m et al (2009) 
(1)
45 with PAD 
and intermittent 
claudication. 
GM-CSF (N=29) 
vs. placebo 
injections (N=16) 
three times weekly 
for two weeks. All 
participants were 
instructed to 
exercise.
CD34+ cells, 
brachial artery 
FMD, and 
walking 
performance at 
12-week follow-
up.
GM-CSF was 
associated with 
significant increases in 
CD34+ cells, brachial 
artery FMD, and 
treadmill performance, 
compared to placebo.
1. Small sample size.  
2. Participants  
exercised on their 
own.  Exercise 
adherence was not 
measured and is 
known to be poor in 
PAD (36).  
IC- Intermittent claudication.  PAD- Peripheral arterial disease.  ABI- Ankle brachial index. FMD-Flow mediated dilation.
 A6.  Supervised treadmill exercise may increase responsiveness to GM-CSF therapy in PAD.  Treadmill 
exercise induces lower extremity tissue ischemia in patients with PAD.  Experimental and animal research 
demonstrate that tissue ischemia and hypoxia promote release of progenitor cells from bone marrow and 
encourage homing of progenitor cells to ischemic sites (37-41).  Homing of progenitor cells to ischemic sites is 
mediated by up-regulation of progenitor cell receptors in target tissues (i.e. calf muscle) and by up-regulation of 
tissue receptors on progenitor cells (37-43).  Myocardial ischemia increases responsiveness to G-CSF in 
patients with coronary artery disease (40).  Together, these data suggest that tissue ischemia, such as that 
induced during supervised treadmill exercise, may increase responsiveness to GM-CSF.  However, whether 
GM-CSF combined with supervised treadmill exercise improves functional performance more than either GM-
CSF alone or supervised treadmill exercise alone is unknown.
A7.  Supervised treadmill exercise may improve walking performance in patients with PAD by 
increasing circulating progenitor cell levels.  Our prior randomized controlled clinical trial (the Study to 
Improve Leg Circulation (SILC)) compared the ability of a supervised treadmill exercise intervention and a 
supervised lower extremity resistance training intervention, respectively, to improve functional performance 
and brachial artery flow-mediated dilation in 156 PAD participants, both with and without intermittent 
claudication symptoms (R01-HL073351) (44).  The primary outcome measure was 6-month change in the 
distance achieved in the six-minute walk test.  Results, summarized below, were published in JAMA (44).   
Table 2. Results of our SILC randomized controlled clinical trial of supervised exercise interventions in PAD 
participants with and without symptoms of intermittent claudication (R01-HL073351) (44).
Absolute change between baseline and 
six-month follow-up
Treadmill 
Exercise (n=50)
Resistance 
Exercise (n=46)
Control group
(n=47)
6 minute walk distance (meters)
+21.281
-2.60
-15.02 
Maximal treadmill walking time (minutes)
+3.691
+2.412
+0.51 
Brachial artery FMD 60 seconds after cuff release (percent). 
+0.70%3
+0.11%
-0.89%
1 p<0.001 vs. control; 2 p =0.009 vs. control; 3 p=0.02 vs. control.  FMD- flow mediated dilation.
As shown in Table 2, our SILC trial demonstrated that supervised treadmill exercise improves walking 
performance and brachial artery flow-mediated dilation (FMD) in PAD participants with and without intermittent 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
5
claudication (44).  SILC was the first randomized controlled trial to demonstrate that supervised treadmill 
exercise improves brachial artery FMD, a measure of endothelial function, in PAD (44).  However, mechanisms 
of the favorable associations shown in Table 2 are unknown.  We hypothesize that supervised treadmill 
exercise may improve outcomes by increasing circulating levels of CD34+ cells.
A8.  Preliminary evidence suggests that walking exercise may increase circulating CD34+ cell levels in 
patients with PAD. Patients with PAD experience calf muscle ischemia during supervised treadmill exercise.  
Experimental and animal studies demonstrate that tissue ischemia promotes endogenous release of progenitor 
cells and increases homing of the progenitor cells to sites of tissue ischemia (37-43).  Several small, 
uncontrolled, or non-randomized trials have demonstrated that exercise increases circulating progenitor cells 
in patients without PAD (21,44-48).  However, people with PAD have fewer circulating progenitor cells and 
exercise at a lower intensity than people without PAD (49,50).  Only one previous publication describes the 
association of exercise training with changes in circulating progenitor cells among patients with PAD (2).  This 
publication reports results from two small randomized controlled trials.  Study A included 18 patients with PAD 
and intermittent claudication without history of lower extremity revascularization.  Study B included 18 patients 
with PAD and intermittent claudication with a history of lower extremity revascularization.  Participants in Study 
A and Study B were randomized to either unsupervised treadmill exercise or no exercise for four weeks.  The 
unsupervised treadmill walking was performed 30 times per week: ten times more frequently than the exercise 
currently recommended in clinical practice guidelines for PAD (2,35).  At four-week follow-up, PAD participants 
randomized to exercise in Study A had significant increases in CD34+ cells, while PAD participants 
randomized to exercise in Study B had no increases in CD34+ cells.  Neither control group experienced 
increases in CD34+ cells. This preliminary work demonstrates that unsupervised treadmill exercise may 
increase CD34+ cells in patients with PAD.  However, the walking exercise intervention was performed 10 
times more frequently than the exercise frequency recommended by PAD clinical practice guidelines (35).  It is 
unknown whether supervised treadmill exercise, performed 3 times weekly, as recommended by current 
clinical practice guidelines, increases CD34+ cells in patients with PAD.   
A9.  Theoretical model for our proposed PROPEL Study.  
Figure 1.  Theoretical Model for Associations of Study Interventions with Improved Functional Performance in 
Participants with Peripheral Arterial Disease
GM-CSF + Lower extremity 
ischemia induced by 
supervised exercise 
Improved functional 
performance
Patients with 
lower extremity 
atherosclerosis
↑ in 
circulating 
CD34+ cells
Improved 
angiogenesis
Vascular repair
Improved 
endothelial function
Improved muscle 
perfusion
Lower extremity ischemia 
induced by supervised exercise 
GM-CSF 
As described in Sections A3 and A4 above, experimental and animal data demonstrate that progenitor cells 
released into the circulation can differentiate into endothelial cells, form new blood vessels (angiogenesis), 
repair injured endothelium, and improve endothelial function (22-24).  Preliminary data also suggest that tissue 
ischemia, such as that induced by walking exercise in patients with PAD, may increase circulating progenitor 
cells and promote their homing to sites of tissue ischemia (37-43).  We hypothesize that GM-CSF combined 
with supervised treadmill exercise maximizes circulating levels of CD34+ cells in patients with PAD and 
improves calf muscle perfusion, by promoting neo-angiogenesis, improving endothelial function, and promoting 
vascular repair.  Figure 1 shows our proposed theoretical model for our study interventions.
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
6
B. INNOVATION
B1.  Innovative features of the proposed PROPEL Study.  First, to our knowledge no prior studies have 
assessed whether the combination of GM-CSF and supervised treadmill exercise improves walking 
performance more than GM-CSF alone or supervised treadmill exercise alone in PAD.  Yet, experimental and 
animal research demonstrate that tissue ischemia and hypoxia, such as that experienced by PAD patients 
during treadmill exercise, promote release of progenitor cells from bone marrow and encourage homing of 
progenitor cells to ischemic sites (37-43). Second, the time course of increases in progenitor cells in response 
to GM-CSF or supervised treadmill exercise among PAD participants is not defined.  Although our primary 
outcome will be measured at 12-week follow-up, the PROPEL study will measure changes in CD34+ cells in 
response to study interventions at 2-week, 6-week, 12-week, and 6-month follow-up.  Our results will help 
define the time-point of maximal improvement and the duration of improvement in study outcomes in response 
to study interventions and associated increases in progenitor cells.  Third, to our knowledge no prior studies 
have directly assessed whether the degree of lower extremity ischemia achieved during treadmill exercise is 
associated with the degree of increase in circulating progenitor cells or the degree of improvement in study 
outcomes. We will measure lactate levels during treadmill exercise sessions to establish whether participants 
who achieve greater increases in lactate during exercise, indicating greater muscle ischemia, have greater 
increases in progenitor cells and greater improvement in study outcomes (see section C7).
B2.  Distinctive features of this trial as compared to prior work.  We are aware of one ongoing randomized 
clinical trial comparing the ability of GM-CSF vs. placebo to improve walking performance in patients with PAD 
(NCT number NCT0104141).  Our proposal has many unique features as compared to this ongoing study.  
First, our proposal will test whether the combination of GM-CSF and supervised treadmill exercise is superior 
to GM-CSF alone and supervised treadmill exercise alone, respectively, for improving functional performance 
in PAD.  Preliminary data support our hypothesis that GM-CSF may be most efficacious when delivered with 
supervised treadmill exercise, but this question is not being addressed by any study to our knowledge.  
Second, by measuring outcomes at six-weeks, 12-weeks, and six-month follow-up, our proposal will assess 
the temporal trajectory of favorable changes in response to GM-CSF with and without exercise therapy.  Third, 
our proposal includes PAD participants both with and without classical intermittent claudication symptoms.  
This is important because most PAD patients do not have classic intermittent claudication symptoms. 
Asymptomatic PAD patients and PAD patients with atypical symptoms have significant functional impairment 
and faster functional decline than people without PAD (6,7,51).  Fourth, whether supervised treadmill exercise, 
at the frequency and duration recommended by clinical practice guidelines (35), increases CD34+ cells in PAD 
participants is unknown. Our proposal will help establish whether increases in CD34+ cells mediate the 
favorable effects of supervised treadmill exercise in PAD.  Fifth, we will use the six-minute walk test as our 
primary outcome measure.  Our data and that of others demonstrate that the six-minute walk test is a better 
measure of community walking ability than treadmill testing in patients with PAD (see Section C12) (52-54).  
B3. Additional innovative features.  A unique feature of the proposed PROPEL study is the planned 
comparison in change in walking performance between two interventions that are each expected to increase 
circulating CD34+ cells.  If supervised treadmill exercise and GM-CSF each increase circulating CD34+ cells, 
but only the groups receiving supervised treadmill exercise improve walking performance, this result will 
demonstrate that increasing circulating levels of CD34+ cells is not sufficient to improve walking performance 
in PAD.  Additionally, if supervised exercise alone and GM-CSF alone each improve walking performance, but 
their combined benefit does not exceed either intervention alone, this finding would suggest a ceiling effect for 
the ability of interventions that increase CD34+ cells to improve walking performance in PAD.  This proposed 
study is expected to identify biological pathways associated with improved functional performance in 
participants with PAD. In turn, this information is expected to lead to new therapies to help patients with PAD 
improve their functional performance and avoid decline.  If our results demonstrate that increasing circulating 
levels of CD34+ cells is associated with improved walking performance, then future studies are expected to 
focus on methods that maximize circulating levels of CD34+ cells to improve walking performance in PAD.  
C. METHODS
All data will be collected for research purposes only.
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
7
C1a. PRELIMINARY DATA.  Our multidisciplinary investigative team includes internationally recognized 
experts in PAD, progenitor cells, exercise training, endothelial function, and functional performance.  Since 
1998, our observational work on functional impairment and decline in PAD has been funded by six R01 awards 
from the National Heart Lung and Blood Institute (NHLBI), led by Dr. McDermott.  Our prior work establishes 
that participants with PAD, both with and without classic symptoms of intermittent claudication, experience 
significant declines in walking performance over time (7,51,55).  Even asymptomatic PAD participants have 
greater impairment in functional performance and faster rates of functional decline compared to those without 
PAD (7,51,55-57).   Since 1998, our group has completed more than 75 original research articles on PAD.  
Three or more of these original research manuscripts have been published in JAMA, Annals of Internal 
Medicine, Circulation, Journal of the American College of Cardiology, and other widely circulated journals.  
Our ability to successfully complete this proposed study is demonstrated in part by our recently completed 
randomized controlled trial of exercise in PAD participants both with and without intermittent claudication 
symptoms (the SILC trial, R01-HL073351) (44). SILC was the first study to test the ability of an exercise 
intervention to improve walking performance in PAD participants with and without intermittent claudication 
symptoms.  SILC was also the first randomized controlled trial to test the ability of an exercise intervention to 
increase brachial artery FMD in PAD participants.  Results were published in JAMA (44) and are described in 
section A7.  Mechanisms by which supervised treadmill exercise improves outcomes in PAD are not 
established.  The current proposal builds on our prior work.  We will assess whether supervised treadmill 
exercise increases the ability of GM-CSF to improve walking performance in PAD, establish whether 
supervised treadmill exercise increases circulating CD34+ cells in participants with PAD, and determine 
whether the degree of increase in circulating CD34+ cells correlates with the degree of improvement in walking 
performance and brachial artery FMD in participants with PAD. Our proposed PROPEL study is expected to 
identify biological pathways associated with improved functional performance in participants with PAD.
C1b.  Test re-test reliability analysis of progenitor cell measures in our laboratory.  In preparation for our 
proposed PROPEL study, we assessed test re-test reliability of our progenitor cell measures.  Progenitor cells 
were measured in 29 participants with and without PAD on two separate days, 1-2 weeks apart.  Progenitor 
cells were measured in Dr. Douglas Losordo’s laboratory at Northwestern.  Table 3 shows our results.
Table 3.  Results of test re-test reliability analysis for progenitor cell measures in our laboratory (n=29)
Test
CD34+
ALDH+
CD34+/CD133+
Mean value (cells/ml)
635.3
812.0
509.4
Intra-pair standard deviation
72.8
75.2
60.7
Technical Error (%)
11.46
9.26
11.91
Table 3 results demonstrate excellent test re-test reliability of progenitor cell measures in our laboratory.  
C1c.  Associations of progenitor cell levels with six-minute walk performance.  We also studied 
associations of circulating CD34+ cells with six-minute walk test performance among the 19 participants with 
PAD in our pilot study.  As shown in Table 4, higher numbers of circulating CD34+ cells are associated with 
greater distance achieved in the six-minute walk among PAD participants.
Table 4.  Associations of circulating progenitor cell concentrations with six-minute walk distance among PAD 
participants in our pilot study (n=19)*
Correlation Coefficient with six-minute walk
P Value
CD34+ cell concentration
0.44
0.06
CD34+/CD133+ cell concentration
0.38
0.11
*Excludes pilot study participants without PAD.
In addition, among the 19 PAD participants, six-minute walk distance across tertiles of CD34+ cells were 
Tertile 1 (fewest CD34+ cells): 1,063 feet + 438; Tertile 2: 1,306 feet + 347; Tertile 3 (largest number of CD34+ 
cells): 1,394 feet + 268, p trend = 0.18.  In summary, our preliminary data demonstrate that higher 
concentrations of CD34+ cells are associated with better six-minute walk performance.  
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
8
C1d.  Additional evidence of our expertise with progenitor cells and PAD.  Dr. Losordo recently 
completed a randomized controlled trial of 28 PAD participants with critical limb ischemia who were 
randomized to either a control group vs. CD34+ cell mobilization, apheresis, and re-injection of CD34+ cells 
into calf muscle.  At six-month follow-up, amputation-free survival was significantly higher among those 
receiving CD34+ cell calf injections as compared to the control group (hazard ratio =0.26, p=0.016).  This study 
provides additional evidence of our expertise and the benefits of CD34+ cells for patients with PAD.
Preliminary Data Summary.  Our prior work has established that people with PAD, both with and without 
intermittent claudication symptoms, have greater functional impairment and faster rates of functional decline 
compared to those without PAD (6-8,51,55-57).  Our SILC randomized trial of exercise demonstrated that a 
supervised treadmill walking exercise intervention significantly improves walking performance and brachial 
artery flow-mediated dilation in PAD participants both with and without symptoms of intermittent claudication 
(44).  Our pilot data demonstrate that higher concentrations of CD34+ cells are associated with better walking 
performance in PAD.  Our preliminary work demonstrates the validity, reliability, and feasibility of our methods.
C2. STUDY OVERVIEW.  The PROPEL study design is a randomized controlled clinical trial of 240 
participants with PAD who will be randomized to one of four study arms in a 2 x 2 factorial design: Group A: 
GM-CSF and supervised treadmill exercise; Group B: GM-CSF and attention control condition; Group C: 
placebo injections and supervised treadmill exercise; Group D: placebo injections and attention control 
condition (Figure 2).  Potentially eligible participants will be required to successfully complete a two-week 
combined exercise/attention control run-in period prior to randomization.  The run-in will help identify potential 
participants unlikely to adhere to study requirements (58).  
Table 5 summarizes characteristics of the four study intervention groups.
Table 5.  Four Study Arms
Supervised Treadmill Exercise
Attention Control Condition
GM-CSF
Group A.  GM-CSF injections x 2 weeks +
 Supervised treadmill exercise x 6 months
Group B.  GM-CSF injections x 2 weeks +
Attention control condition x 6 months.
Placebo
Group C.  Placebo injections x 2 weeks + 
Supervised treadmill exercise x 6 months.
Group D.  Placebo injections x 2 weeks +
Attention control condition x 6 months.
Table 6 shows the data collection planned at each time point.  Our primary outcome is change in six-minute 
walk performance between baseline and 12-week follow-up.  
Table 6.  Data Collection Schedule for PROPEL Study
Baseline
Two-week 
follow-up
Six-week 
follow-up
Twelve week 
follow-up*
Six-month 
follow-up
Six-minute walk.
X
X
X
X
CD34+ cells and other progenitor cell measures
X
X
X
X
X
Brachial artery flow-mediated dilation. 
X
X
X
X
Treadmill walking performance.
X
X
X
X
*Time point of primary outcome measurement
We have not powered the study to test for an interaction between the two therapies. We are not necessarily 
looking for more than an additive benefit of GM-CSF with supervised treadmill exercise as compared to GM-
CSF alone and supervised treadmill exercise alone. This is because any additional significant improvement in 
walking performance from combining GM-CSF and supervised treadmill exercise, compared to either therapy 
alone, will have significant clinical implications for PAD therapy.    
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
9
C3. Inclusion Criteria.  All participants will have PAD.  PAD will be defined as follows.  First, an ABI < 0.90 at 
the baseline study visit is an inclusion criterion for PAD (60-63).  ABI < 0.90 is a well accepted standard for 
defining PAD (60-63). Second, potential participants who have an ABI > 0.90 but ≤ 1.00 and experience a 20% 
drop in ABI after the heel-rise exercise will be eligible. Third, potential participants who have an ABI > 0.90 but 
have a documented lower extremity revascularization procedure and experience a 20% drop in ABI after the 
heel-rise exercise will be eligible.  Fourth, potential participants with an ABI > 0.90 who have vascular lab 
evidence of PAD will be eligible.
C4.  Exclusion Criteria.  Exclusion criteria and justification for each criterion follow.  1.  Potential participants 
with below or above-knee amputation or critical limb ischemia, those who are wheelchair confined, those who 
use a walking aid other than a cane (i.e. people using walkers), those who are non-English speaking, those 
with significant hearing or visual impairment, and those unable to return to the medical center three times 
weekly will be excluded because these individuals will not be able to participate fully in our intervention; 2. 
Potential participants diagnosed with Parkinson’s disease and individuals whose walking is limited by a 
symptom other than PAD will be excluded because our intervention is designed specifically for individuals 
whose walking is limited by leg ischemia.  3. Potential participants with > Class II New York Heart Association 
heart failure or angina, an increase in angina symptoms during the previous 6 months, angina at rest, severe 
aortic stenosis, coronary ischemia during the baseline exercise treadmill test, those with a left-bundle branch 
block or significant ST-T wave changes on the baseline ECG precluding interpretation of the baseline exercise 
treadmill test, those who stop during the treadmill stress test for shortness of breath, chest pain, hip pain, knee 
pain, or another symptom that may not represent ischemic leg pain, stopping during the six-minute walk test for 
symptoms other than ischemic leg pain, or a foot ulcer will be excluded because it may not be safe for them to 
enter an exercise program. 4. Potential participants who have had lower extremity revascularization during the 
past three months, those with major orthopedic surgery during the past three months, those with myocardial  
infarction, ischemic stroke, or coronary artery bypass grafting during the previous three months, and those 
contemplating lower extremity revascularization during the next six months will be excluded because these 
events may influence study outcomes, independently of the study interventions; 5. Potential participants with 
major medical illnesses including renal disease requiring dialysis or lung disease requiring oxygen will be 
excluded because these and other major medical illnesses may prevent their full participation in the study. 
Participants who use oxygen at night may still qualify. 6.  Potential participants with a Mini-Mental Status 
Examination (MMSE) score < 23 (64) or disabling psychiatric illness will be excluded because these conditions 
may prevent their full study participation or ability to provide accurate responses to questionnaires; 7. Potential 
participants enrolled in cardiac rehabilitation during the past six months and those who are either currently 
enrolled in another clinical trial or who have been enrolled in another clinical trial during the past three months 
will be excluded because these interventions may alter outcome measures, independently of study 
interventions.  However, for a clinical trial of stem cell or gene therapy intervention, potential participants will be 
potentially eligible immediately after the final study visit of the stem cell or gene therapy clinical trial, so long as 
at least six months has passed since the participant received their final treatment in the stem cell or gene 
therapy intervention. 8.  Potential participants already walking for exercise at a level comparable to that 
targeted in the exercise intervention and those receiving G-CSF, GM-CSF, or erythropoietin within the past 
year will be excluded because these interventions may influence study outcomes independently of the 
interventions.  9. Pre-menopausal women will be excluded because cyclic estrogen changes can influence 
progenitor cell levels.  10. Potential participants with diabetes and documented proliferative retinopathy, those 
with history of myeloid malignancy, and those treated for late stage cancer during the previous three years will 
be excluded because GM-CSF may exacerbate these conditions. 11. Potential participants who fail to 
complete the study run-in requirements will be excluded because it may be difficult for them to adhere to the 
study requirements; 12. Potential participants who are deemed poor candidates for the study may be excluded 
at the discretion of the principal investigator.  For example, potential participants who are argumentative or 
disruptive during study visits may not be well suited to the program.   
C5.  Recruitment.  We will identify and randomize 267 PAD participants over 49-months, allowing for a 10% 
drop-out at 6-month follow-up (see timeline in our budget justification).  This projected 10% drop-out rate is 
greater than the six-month drop-out rate of 7.7% in our recently completed SILC randomized controlled 
exercise clinical trial (44). Thus, our projected drop-out rate is reasonable.  As in our previous clinical trials of 
patients with PAD, we will identify potential participants with the following methods:  1) Use of Northwestern’s 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
10
Enterprise Data Warehouse to identify consecutive patients with PAD or patients at high risk for having PAD 
from Northwestern Medicine, including the Regional Medical Group in the western suburbs. We will contact 
physicians via phone, email, page, or fax prior to contacting their patients. If physicians do not reply within 
three weeks, up to five letters will be sent directly to the patient three weeks apart; 2) television, radio and 
newspaper advertising; 3) postcard mailings to men and women living in the wider Chicago area; 4) Mailed 
letters to participants in the Lifeline Screening program who were found to have PAD;  5) Study brochures and 
information flyers. 6) Mailed letters to University of Chicago patients with known PAD. A research coordinator 
at the University of Chicago will provide a list of patients with known PAD and NU coordinators will send letters, 
signed by a UofC physician, and make follow-up calls from UofC. 7) Mailed letters to Jesse Brown VA Medical 
Center patients with known PAD. A research coordinator with WOC status at JBVAMC will send letters to 
JBVAMC patients with PAD and make follow-up calls from JBVAMC. Participants recruited through these 
methods will sign a VA consent document and will undergo some study testing on-site at the VA. Study tests 
include questionnaires and functional performance measures. We have successfully used each of these 
methods in our prior or ongoing clinical trials of patients with PAD.  
Evidence of our experience successfully recruiting PAD participants for NHLBI-funded studies:  In the 
past five years we have randomized > 463 PAD participants into NHLBI-funded clinical trials.  In addition, since 
1998, we have enrolled more than 1,800 men and women with PAD into our NHLBI-funded studies (R01-
HL58099, R01-HL073351, R01-HL071223, R01-HL073912, R01-HL083064, and R01-HL089198).  We have 
accomplished this using methods described above and by partnering with other Chicago medical centers.
C6. Randomization.  Participants will be randomized to one of four arms using a SAS computer program (see 
Table 5).  Participants will be stratified by diabetes mellitus, since patients with diabetes have fewer progenitor 
cells than those without diabetes (49,50).  Based on our prior work, we anticipate that approximately 25% to 
30% of participants will have diabetes (44).  Block randomization will be implemented to ensure balance 
between the four groups throughout recruitment.  Block sizes will be randomly selected from eight and twelve.
C7. Supervised treadmill exercise program.  Our exercise training protocol is based on prior studies, 
including our SILC clinical trial of exercise in PAD, and is consistent with current clinical practice guidelines for 
PAD patients (35,44,65-67).  Our exercise intervention will be delivered three times weekly.  In the first week, 
participants will be asked to exercise 15 minutes per session (excluding rest periods).  Walking exercise 
duration will be increased by five minutes per session each week until 40 to 50 minutes of exercise per session 
is achieved (35).  At this point, exercise intensity will be increased by alternately increasing treadmill speed and 
treadmill grade.  Exercise intensity will be set to ensure that at each exercise session, participants experience 
ischemic leg symptoms within eight to ten minutes after onset of exercise.  Participants will be asked to 
continue walking until they achieve leg symptom severity of “4 or 5” on a visual analog pain scale ranging from 
1 to 5.  After achieving leg symptom severity of “4 or 5” on the pain scale, participants will be allowed to rest 
until they are able to resume walking again (i.e. when pain reduces to a 2 or 1 on the scale). This method will 
help ensure that calf muscle ischemia is induced, releasing nitric oxide and vascular endothelial growth factor, 
which in turn promote release of progenitor cells (68,69).  In the subset of participants without exertional leg 
symptoms (i.e. those with asymptomatic PAD), participants will be asked to exercise to achieve a Borg Rating 
of Perceived Exertion (RPE) score of 12-14 (70-73).  To ensure that exercise intensity is sufficient to achieve 
an anaerobic state during exercise, we will measure lactic acid levels every two to four weeks at the beginning 
and end of exercise sessions.  Participants whose lactic acid does not increase during exercise will have their 
exercise intensity increased at the next session and will be even more closely monitored for exercise intensity.   
C8. Attention Control Group.  Our attention control group will control for the possibility that regular contact 
with the study team may improve outcomes in participants randomized to supervised exercise.  Participants 
randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern 
University for six months.  These educational sessions are on topics of interest to the typical PAD patient and 
are led by physicians and other health care workers.  Topics include Medicare Part D, nutritional supplements, 
C-reactive protein, and hypertension.  Sessions do not include information about exercise.    
C9. GM-CSF or placebo injections. GM-CSF or placebo will be administered subcutaneously by a registered 
nurse or physician, three times weekly for two weeks, in a double-blinded fashion (i.e. both investigators and 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
11
participants will be blinded to receipt of medication vs. placebo).  GM-CSF will be used because the most 
promising data regarding the association of colony stimulating factors with improved walking performance in 
PAD participants used GM-CSF (1).  In addition, GM-CSF may be associated with a lower risk of thromboses 
than G-CSF (1). The dose of GM-CSF will be 250 ug/m2/day
subcutaneously three times weekly for two weeks (1).  Higher doses of GM-CSF are not FDA approved.  The 
most promising preliminary study of GM-CSF to improve walking performance in PAD patients used doses of 
3, 6, and 10 ug/kg administered three times weekly (1).  Although there was no clear linear dose-response 
association, the doses of 6 ug/kg and 10 ug/kg achieved the greatest number of circulating CD34+ cells, 
compared to the lower dose (1).  The proposed dose of 250 ug/m2/day is expected to maximize benefit while 
minimizing side effects.   To monitor for adverse effects, we will measure white blood count (WBC) once each 
week during the two weeks that the GM-CSF is administered. Additional WBCs might be measured at the 
discretion of the Safety Monitor, during the time period that study medication is administered. The study drug 
will be discontinued if the participant experiences an arterial thrombotic event or is hospitalized for a reason 
that may be related to the study drug. If a participant is hospitalized for a reason that may be related to the use 
of the study drug, the decision to reduce the drug dosage or discontinue the drug will be made by study safety 
officers Dr. Green or Dr. Lloyd-Jones on a case-by-case basis. In general, if a patient is suspected of acute 
coronary syndrome or a new significant arrhythmia, their study drug injections will be withheld until appropriate 
medical work-up is completed. If the participant is determined NOT to have an acute coronary syndrome, 
active coronary disease, or a significant arrhythmia, the participant may resume full does of the study 
medication. However, if the participant is determined to have an acute coronary syndrome or active, significant 
arrhythmia, then additional receipt of study drug, at full-dose or reduced does, will be made on a case-by-case 
basis by the study safety officers. The study nurse will have Tylenol available in the event of acute muscle pain 
following the study injection. The Tylenol will be provided by NMH pharmacy and administered at a maximum 
dose of 1000mg.  
Monitored Walking Program:  Potentially eligible study participants will be telephoned by study staff and 
invited to participate in this walking program.  Interested participants will be asked to come to our walking 
exercise facility (i.e. Northwestern Memorial Hospital’s Cardiac Rehab program) or to Northwestern Memorial 
Hospital where they will be provided with a device, an accelerometer and/or a pedometer that tracks their 
walking exercise activity.  They will be shown how to use their device.  They will be asked to use their device to 
monitor their activity, including walking exercise activity.  They will be shown how to transmit the data from their 
accelerometer/pedometer back to the study coach.  They will also be asked to record data on exercise time 
and distance using a paper tracking form.   They may also be asked to send a text message to the study coach 
at the start and end of each walking exercise session, with details about their walking activity including the 
duration and intensity of each walking exercise bout.  
In this monitored walking program, participants will be randomized to walk for exercise at low intensity (with 
minimal to no leg symptoms) or high intensity (with maximal leg symptoms during exercise activity).  
Participants will be asked to walk around the track at the exercise facility or up and down a hallway at 
Northwestern Memorial Hospital in order to learn the pace to walk according to their assignment to low 
intensity or high intensity exercise.  Participants will then be helped to set targets (i.e. goals) for walking activity 
during the next week.  They may be asked to return to the exercise center for additional coaching, for up to 
four additional sessions.
Participants will be provided with walking exercise “tracking” forms and asked to write down their goals for 
home-based walking activity each day for the next two weeks and record where and when they will exercise.  
They will be provided with “tracking’ sheets on which to record their walking activity for each week that they are 
in the walking exercise program.   After this initial on-site visit, study participants will be telephoned weekly for 
up to 14 weeks by a study coach who will review their walking exercise activity and provide feedback and 
encouragement.  Participants may be visited at home or at their own exercise facility to monitor walking 
intensity. Each telephone call will last approximately 15 minutes.  Participants will be asked to complete some 
study questionnaires before and after their participation in this program. They will be asked to return to the 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
12
medical center for final follow-up when they have completed the program.  They will return their monitoring 
devices at their final visit.  
Computerized Tablet or Computer Camera Study Visit: Potentially eligible study participants will be 
telephoned by study staff and informed of the option of returning for a visit where they will be taught how to 
operate a tablet or camera. Specifically, they will be taught how to link to video chat on the tablet or camera. 
They may be asked at a later date to participate in up to three video chat sessions, in which they use their 
tablet or computer camera at home to connect with a group leader and other study participants with peripheral 
artery disease. The video chat sessions will last one hour or less.  Participants will be asked to return the 
tablets or cameras to investigators at the end of the pilot study.
MRI to measure lower extremity perfusion: To measure lower extremity blood flow or perfusion, we will use 
techniques in a subset of up to 50 participants who provide informed consent to this optional study element.  In 
the MRI machine, we will ask participants to push against a plastic board with their feet (i.e. a plantarflexion 
motion) repeatedly at a rate of one push per second.  A metronome will be used to monitor the rate of pushing.  
Participants will be asked to push for as long as they are able. When they are too tired to continue, they will 
rest and perfusion to the calf muscle will be measured using MRI. This test will be conducted on a Siemens 
Tim Trio 3 Tessalon MR or a Siemens Skyra 3 Tessalon scanner at the Center for Translational Imaging (CTI) 
in the Olson Pavilion at Northwestern. If the designated Tim Trio or Skyra 3.0 Tessalon scanner is unavailable, 
we will use a different 3.0 Tessalon scanner at Northwestern Memorial Hospital or the center for CTI. We may 
perform up to 3 perfusion MRI scans on individual participants, in order to conduct a test re-test reliability 
assessment. We will not use any contrast for this method.  
OUTCOME MEASURES.  
C10.  Justification for measuring primary outcomes at 12-week follow-up.  We recognize that the time 
point at which study outcomes are maximally improved following GM-CSF therapy is unknown.  The half life of 
GM-CSF is 162 hours (75).  Peak levels of circulating CD34+ cells are observed 5-6 days after onset of GM-
CSF therapy and subsequently decline even with continued GM-CSF injections (1,74,75).  However, available 
evidence supports measurement of our primary outcomes at 12-week follow-up.  First, a previous uncontrolled 
clinical trial of 17 patients with PAD and critical limb ischemia demonstrated measurable improvement in toe 
brachial pressure index, TcPO2, and pain free walking distance four-weeks after CD34+ cells were injected 
into calf muscle of participants (76). These improvements persisted or even further improved at 24-week 
follow-up (76).  In a separate study, 22 patients with bilateral PAD were randomized to receive calf injections of 
autologous bone-marrow derived mononuclear cells vs. peripheral blood derived mononuclear cells (77).  
Four-weeks after the injections, measurable improvements in transcutaneous oxygen pressure and rest-pain 
were observed in the leg receiving bone-marrow derived cells compared to the leg receiving peripheral 
mononuclear cells (77).  These improvements were sustained at 24-week follow-up. Third, in the study by 
Subramaniyam and colleagues, two-weeks of GM-CSF therapy was associated with improved treadmill 
walking performance and brachial artery FMD at 12-week follow-up (1).  Similarly, in studies of patients with 
coronary artery disease, improvements in cardiac ejection fractions or regional wall motion abnormalities are 
typically first observed four to 12 weeks after < two weeks of GM-CSF therapy (78-80).  These improvements 
are maintained or even increase during follow-up periods of up to one year (78-80).  In summary, although the 
optimal time point for measuring improved outcomes in response to GM-CSF is not established, available data 
suggest that 12 weeks after therapy onset is a reasonable time point for measuring our primary outcomes.  
Similarly, significant improvements in treadmill walking performance are observed 12-weeks after initiation of a 
supervised treadmill exercise intervention (35,65-67).  Our exploratory aim will assess the time course of 
improved outcomes in response to GM-CSF therapy with and without exercise.     
C11.  Justification for measuring CD34+ cells as the primary progenitor cell outcome.  We recognize 
that no single cell-surface marker is completely specific for endothelial progenitor cells (31).  However, the 
CD34+ marker clearly identifies a population of functional progenitor cells that are released into the circulation 
in response to tissue ischemia, have the potential to differentiate into endothelial cells, and promote 
angiogenesis (22,31,32,76).  Based on these prior data, CD34+ cells will be our primary progenitor cell 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
13
outcome measurement. Please see sections A3 and A4 for further discussion of this issue.  In exploratory 
analyses, we will also measure CD133+ cells, KDR+ cells, ALDH bright cells, combinations of these cell 
markers, and progenitor cell colony forming units.  It is important to point out that, compared to CD34+ cells, 
these exploratory progenitor cell measures have not been as consistently linked to favorable outcomes in 
patients with cardiovascular disease. Progenitor Cell Measures.  CD34+ cell measurements will take place in 
Dr. Losordo’s laboratory using methods implemented for our pilot study (see sections C1b and C1c).  Total 
human peripheral blood mononuclear cells (MNCs) are isolated from the blood of participants by Ficoll density 
gradient centrifugation with Histopaque-1077 (Sigma), according to the manufacturer’s instructions. Briefly, 
MNCs are aliquoted (5x105) to an Aldecount tube, incubated with BODIPY-AAD for 30 minutes at 37°C, and 
maintained on ice to prevent fluorescent byproduct exiting cells. Cells are washed in ALDH assay buffer at 4 
degrees Celsius for 5 minutes and re-suspended in 90ul ALDH Assay buffer for further staining. ALDH labeled 
MNCs are incubated with FcR Blocking Reagent (Miltenyi Biotec) for 10 minutes followed by specific FACS 
antibodies for 30 minutes on ice to identify the CD34-PE Cy7 (Beckman Coulter) endothelial marker (primary 
outcome) and other cell surface markers (exploratory outcomes).  These exploratory cell markers include 
CD133-APC (Miltenyi Biotec) and VEGF R2 / KDR-PE (R&D Biosystems). Dead and dying cells are excluded 
using staining with 7-AAD (1 µg/106 cells; Invitrogen). Directly conjugated isotype control antibodies are used to 
set baseline fluorescence levels. Flow cytometry is performed by Northwestern’s Cancer Core Research 
facility, blinded to patient identity and group assignment using the DakoCytomation CyAn FACS instrument.  
Analyses are performed using the FlowJo software (Treestar). Gating mononuclear cells is performed on the 
basis of light-scattering properties. The labeled cells of interest (i.e. CD34+ cells) are expressed as 
percentages of live mononuclear cells.  Progenitor cell colony forming unit assay.  Total human peripheral 
blood mononuclear cells (PBMNC) will be isolated from blood by Ficoll density gradient centrifugation with 
Histopaque-1077 (Sigma) according to manufacturer instructions. PBMNC will be re-suspended in endothelial 
cell basal medium-2 (EBM-2, Clonetics) supplemented with 5% FBS, human vascular endothelial growth factor 
(VEGF)-A, human fibroblast growth factor-2, human epidermal growth factor, insulin-like growth factor-1, 
ascorbic acid, and antibiotics and then plated on fibronectin-coated 6 well plates at a concentration of 5 million 
cells per well. The endothelial colonies will be counted manually on day 7 by two investigators blinded to the 
study group assignments. Progenitor cells will be further characterized by dual-staining for DiI-Ac-LDL and 
Lectin and by the expression of endothelial marker proteins VEGFR-2, VE-cadherin, eNOS, and vWF. 
In addition to measuring progenitor cells at the frequency shown in Table 6 above, in up to 50 participants with 
PAD we will measure progenitor cell levels before and immediately following the treadmill exercise stress test.  
We may also measure progenitor cell levels one hour post-exercise and one day post-exercise. The treadmill 
exercise stress test at which this may occur may be affiliated with any of the visits shown in Table 6.  However, 
it is possible that the participant may be asked to undergo an additional treadmill exercise stress test in order 
to expedite collecting data on progenitor cell levels before and after an exercise stress test. Also- up to 30 
participants who are determined ineligible for the study due to absence of PAD will be invited to participate in 
an exercise treadmill stress test.  Levels of progenitor cells will be measured before and after the exercise 
treadmill stress test in these individuals without PAD as well as one hour post-exercise and one day post-
exercise.  These additional procedures will allow us to achieve our exploratory aim #5 above. 
C12.  Six-minute walk.  Our primary outcome is change in the distance achieved in the six-minute walk test 
between baseline and 12-week follow-up.  The six-minute walk is our primary outcome measure for several 
reasons.  First, our work demonstrates that for PAD participants, performance on the six-minute walk test is 
more closely correlated with walking performance during daily life than treadmill walking performance (81).  
Secondly, for elderly patients, such as those with PAD, treadmill walking is associated with balance problems 
and anxiety (52-54).  A previous study of 12 healthy elderly volunteers (ages 71-80 years) and 12 healthy 
young volunteers (ages 21-37) compared physiologic responses and steps per minute during a treadmill 
exercise test vs. the six-minute walk (corridor walking) performed on three separate occasions (52).  The 
elderly group, but not the younger group, had consistently higher heart rates and lower step rates during the 
treadmill test than during the corridor walks (52).  Third, treadmill walking is associated with a significant 
learning effect (82-84).  Supervised treadmill exercise interventions, such as that proposed in the current study, 
can improve treadmill walking performance in part because of the “practice” associated with the three times 
weekly treadmill exercise sessions.  In the six-minute walk, participants walk back and forth along a 100-ft 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
14
hallway for six minutes after standardized instructions to complete as many laps as possible (44,81,85).  
Distance covered in six minutes is recorded.  The intra-class correlation coefficient for the test-retest reliability 
of the six-minute walk test among 156 PAD participants in our SILC exercise trial was 0.90 (p<0.001) when two 
six-minute walk tests were completed one to two weeks apart (44). 
C13. Treadmill testing.  The Gardner graded treadmill exercise test is the standard, accepted treadmill 
protocol for measuring change in maximal treadmill walking time in response to interventions among PAD 
participants (82-84).  The FDA requires treadmill evidence when evaluating therapeutic drugs for improving 
walking performance in PAD.  In the Gardner exercise protocol, speed is maintained at 2.0 miles per hour 
(mph) and treadmill grade increases by 2.0% every two minutes (82-84).  If patients cannot walk at 2.0 mph, 
treadmill speed is started at 0.50 mph and increased by 0.50 mph every 2 minutes until the participant reaches 
2.0 mph, after which the treadmill grade is increased every two minutes.  
C14.  Brachial Artery Flow-Mediated Dilation (FMD).   As in our prior studies (44,86,87), brachial artery 
imaging will be performed by a Registered Diagnostic Cardiac Sonographer (44,86,87).  Participants withhold 
vasoactive medications, refrain from smoking, and fast prior to testing (86,86).  With the participant supine, a 
blood pressure cuff over the upper arm is inflated for four minutes. The inflation pressure is systolic blood 
pressure (SBP) + 50 mmHg.  The brachial artery is imaged (B-mode and Doppler) 5 to 9 cm above the 
antecubital fossa using a linear array vascular ultrasound transducer (Siemens Medical Solutions, Sequoia 
Model #256, frequency 8 MHz). Three video sequences are obtained.  The first verifies the location and 
baseline hemodynamic state of the brachial artery.  The second begins 20 seconds before cuff inflation and 
continues for 10 seconds after inflation.  The third begins 15 seconds before cuff release and continues for 90 
seconds after deflation.  Brachial artery FMD is calculated as the percent change in brachial artery diameter at 
60 seconds after the release of the cuff.  Because previous studies of coronary artery disease patients 
consistently show that brachial artery endothelial independent function does not change in response to 
interventions, we will not measure nitroglycerin-mediated vasodilation (89,90).  Changes in brachial artery FMD 
will be read by Dr. James Stein’s University of Wisconsin Atherosclerosis Imaging Research Program Core 
Laboratory.  Images are read by a single reader blinded to participant characteristics.  Measurement 
reproducibility in Dr. Stein’s laboratory has a median FMD difference of 0.02% (inter-quartile range: -0.03–
0.04). 
C15.  Other measures.  As in our previous clinical trials, patient report will be used to document comorbidities.  
Patient reported comorbid disease is highly correlated with presence of comorbid disease measured with 
medical record review (91-95).  In the National Hospital Discharge Survey of 122 elderly men and women, the 
percent agreement between patient report and medical record review was 85% for angina, 89% for cancer, 
98% for diabetes, 94% for myocardial infarction, and 98% for stroke (92). Participants will be asked to bring 
their medication bottles for assessment of medication use at baseline and at follow-up visits.  Patient-report is 
an accurate measure of cigarette smoking in PAD patients (96).
Some or all study measures may be repeated at baseline or follow-up for data quality (one potential example is  
if a treadmill test must be stopped due to extremely high blood pressure before the patient completed the test).
C16. Quality Control.  As in our prior studies, health interviewers will be trained by a senior coordinator and 
certified by Dr. McDermott in each component of data collection, using a detailed checklist developed for the 
study (see Appendix A for example checklist).  Health interviewers are rigorously evaluated for adherence to 
protocol, delineated in our manuals, prior to beginning data collection and every six months after initial 
certification.  When deficiencies are identified, interviewers undergo additional training and re-assessment. Ten 
percent of participants are randomly identified for quality control.  This subset has their ABI measured twice by 
independent examiners and has an extra blood sample obtained for quality control assessment of progenitor 
cells.  The second blood sample is designated an arbitrary identification number to which the technician is 
blinded.  Thus, quality control is monitored continuously.  A randomly selected 10% subset of exercise session 
charts will be reviewed by Dr. McDermott to ensure protocol adherence.  Dr. McDermott also attends one or 
more exercise sessions on a monthly basis to ensure adherence to protocol.  Furthermore, during the first year 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
15
of the study, 10 participants will be selected for a second brachial artery FMD. These participants will be asked 
to return within two weeks (1-14 days, but not on the same day as the first FMD) after their baseline testing 
and before randomization for a repeat brachial artery FMD measurement.  The purpose of this re-test is to 
assess the test re-test reliability of the brachial artery FMD measurement.
C17.  Blinding for data collection.  The health interviewer collecting outcome data will be blinded to the study 
group assignment.  Participants are instructed not to reveal their group assignment.  If a participant reveals 
their group assignment, another certified health interviewer is paged to continue the visit.  
C18.  Data Management.  We will use methods in place for our previous and ongoing PAD studies to 
customize a data management system for the PROPEL Study.  Data from baseline and follow-up visits will be 
acquired on paper and processed using the Teleform system by Cardiff Software.  We have successfully used 
the Teleform system for over 6,000 patient visits in previous and ongoing studies.  Teleform has three 
components.  The first component, the Designer, functions as a page layout program with predefined tools for 
creating check boxes, bar code fields, and hand print fields.  Form packets are assembled and individualized 
with ID labels prior to each visit.  Completed forms are scanned using a high-speed scanner.  The second 
component, the Reader, accepts scanned images and translates user responses (check marks, circles, or 
hand-printed text) into machine-readable responses.  The third component, the Verifier, double-checks user 
responses prior to final acceptance.  The Verifier is programmed with the data validation rules established 
when the form was created.  Data are routinely backed-up and copied to CDROM for secure off-site storage.
C19.  Data and Safety Monitoring Board (DSMB).  As per NHLBI guidelines, the DSMB will be appointed by 
the NHLBI.  The DSMB will review and approve the protocol prior to beginning recruitment.  The DSMB will 
meet every six months.  Adverse events will be monitored continuously throughout the study and will be 
reported to the DSMB and IRB promptly.  See Section D2 below for more information about the DSMB.   
C20. Statistical Power Considerations.  As indicated above, the four study arms are defined as follows:  
Group A: GM-CSF combined with supervised treadmill exercise; Group B: GM-CSF therapy + an attention 
control group; Group C: placebo + supervised exercise; and Group D: placebo + attention control group. From 
this point forward, “GM-CSF combined with supervised treadmill exercise” refers to Group A; “GM-CSF therapy 
alone” refers to Group B, “supervised exercise therapy alone” refers to Group C, and placebo + attention 
control group (i.e. no active therapy) refers to Group D.  
In our primary aim, we will determine at 12-week follow-up: (a) whether GM-CSF therapy combined with 
supervised treadmill exercise (Group A) significantly improves six-minute walk performance compared to GM-
CSF therapy alone (Group B), (b) whether GM-CSF therapy combined with supervised treadmill exercise 
(Group A) significantly improves six-minute walk performance compared to supervised exercise therapy alone 
(Group C) and (c) whether GM-CSF therapy alone (Group B) significantly improves six-minute walk 
performance compared to placebo (Group D).  We will also confirm the previously established association 
between supervised treadmill exercise (Group C) and improved six-minute walk performance, compared to no 
active therapy (Group D).  
The final sample size in the PROPEL Trial, of 210 participants, was lower than the originally intended sample 
size of 240 participants.  Prior to analyzing the data, investigators propose to alter the statistical analysis plan.  
The new statistical analysis plan allows us to address our original hypotheses but with greater statistical power, 
given the slightly lower sample size than originally intended.  The revised statistical plan is as follows.  The 
significance levels of the four primary comparisons will be determined using the Hochberg’s step up method 
rather than the conservative Bonferroni correction.  Specifically, we will sort the p-values from the smallest to 
the biggest as  
.  For the purposes of the analysis plan, the “hypothesis” refers to the 
𝑝(1) < 𝑝(2) < 𝑝(3) < 𝑝(4) 
null hypothesis.  Rejecting all four hypotheses indicates that the hypotheses specified in our specific aims 
above are correct.  Under this assumption, we will 
(1) reject all four hypothesis if 
;  
𝑝(4) ≤0.05
(2) otherwise, we will reject hypotheses (1-3), if 
;  
𝑝(3) < 0.05/2
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
16
(3) otherwise, we will reject hypotheses (1-2), if 
;
𝑝(2) < 0.05/3
(4) otherwise, we will reject the hypothesis (1), if 𝑝(1) < 0.05/4
The Hochberg’s step up method also controls the family-wise type one error and is more powerful than the 
Bonferroni adjustment.
C21. Statistical Analyses Methods.  Change in six minute walking distance at 12-week follow-up is our 
primary outcome.  Changes in brachial artery FMD, maximal treadmill walking time, and CD34+ cells at 12-
week follow-up are secondary outcomes. The distributions of each outcome will be examined and appropriate 
transformations will be performed if necessary.  Prior to the analyses, baseline characteristics (i.e., age, sex, 
race, baseline six-minute walk, ABI, CD34+ cells, and other relevant variables) will be compared between the 
four groups, using a F-test or Chi-Square test to ensure that baseline characteristics are balanced across the 
four groups.  Any variables that are significantly different between groups will be adjusted for as covariates.  
For our Primary Aim, we will compare changes in six minute walk distance from baseline to 12-week follow-up 
between Groups A and B, between Groups A and C, between Groups B and D, and between Groups C and D 
using a two-sample t-test.  Analysis of covariance will be used to adjust for baseline characteristics as 
necessary. For our Secondary Aim, we will compare changes in brachial artery FMD and maximal treadmill 
walking time from baseline to 12-week follow-up between Groups A and B, between Groups A and C, and 
between Groups B and D.  We will also determine whether participants in Group C have greater increases in 
CD34+ cells at 12-week follow-up, compared to Group D.  The two-sample t-test or analysis of covariance will 
be used for these comparisons. Efficiency augmentation methods for estimating the treatment effects using the 
distribution of baseline characteristics will be employed (96). The 95% confidence interval of the treatment 
effects will be constructed.  Because the primary aim of the study is to demonstrate the superiority of Group A 
(GM-CSF + supervised exercise) as compared to Group B (GM-CSF alone) and Group C (supervised exercise 
alone), the commonly used two-way analysis of variance will be used only in supplementary analysis.  
Specifically, for the outcomes of interest in our primary and secondary aims, we will test the interaction 
between GM-CSF and supervised exercise with two-way ANOVA.  In the absence of an interaction (i.e, the p 
value for the interaction term exceeds 0.25), we will further estimate the additive effect of GM-CSF and 
supervised exercise simultaneously in all 240 participants.  Here, the existence of model-based additive effects 
for GM-CSF and exercise is much stronger than the targeted superiority of the combined treatments.  
For our Exploratory Aims, we will use linear mixed effects regression analyses to compare changes in six-
minute walk performance, maximal treadmill walking time, and brachial artery FMD between baseline and six-
week follow-up and between baseline and six month follow-up between Groups A and B, Groups A and C, 
Groups B and D, and Groups C and D.  We will use linear mixed effects regression analyses to compare 
changes in progenitor cell measures between baseline and six-week follow-up and between baseline and six-
month follow-up between Groups C and D.  Outcomes measured at baseline and each follow-up visit will be 
longitudinal response variables in the regression model.  The regression coefficients for the interactions 
between group indicators and visit time are parameters of interest.  The subject specific random intercept will 
be used to incorporate the within subject correlations.  For our Exploratory Aim #4, we will employ linear mixed 
regression analysis to evaluate the association between changes in CD34+ cells and other progenitor cell 
measures from baseline to two-week follow-up with changes in six-minute walk distance, brachial artery FMD, 
and maximal treadmill walking time between baseline and six-week, twelve-week, and six-month follow-up 
visits.  The responses are longitudinally measured outcomes of change between baseline and the six-week, 
twelve-week, and six-month visits, respectively.  The independent variables of interest are changes in CD34+ 
cells and other progenitor cell measures from baseline to two-week follow-up.  We will employ similar linear 
mixed regression analysis to evaluate associations between changes in progenitor cells between baseline and 
six-week, 12-week, and six-month follow-up with changes in six-minute walk distance, brachial artery FMD, 
and maximal treadmill walking time during the corresponding time period.  The responses are longitudinally 
measured outcomes of change between baseline and the six-week, twelve-week, and six-month visits, 
respectively.  Independent variables of interest are changes in progenitor cells from baseline to six-week, 12-
week, and six-month follow-up.  Finally, we will perform regression analyses among participants randomized to 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
17
the exercise group to determine whether the degree of increase in lactate levels during exercise sessions is 
associated with the degree of increase in progenitor cells. 
C22. Intention to Treat.  In all comparisons, we will employ the intention-to-treat principle.  Participants will 
remain in their originally assigned groups for analyses, regardless of adherence to their assigned group.  
Based on our experience in our SILC clinical trial, the drop-out rate is expected to be <10% at six-month 
follow-up.  Therefore, complete case analysis coupled with reasonable sensitivity analysis should be adequate 
to handle the problem of missing data.  If the drop-out rate exceeds five percent, we will employ more 
sophisticated statistical methods such as multiple imputation and the pattern mixture approach to correct for 
the potential bias of estimates from simple complete-case analysis due to informative missing data.  The study 
team has substantial experience employing these methods in prior studies (44,97,98).  We will use the type 
one error value of 0.0125 to cope with multiple comparisons. 
C23. Follow-up window.  Follow-up testing will be completed within one week before or after the target follow-
up date, at the 2-week, 6-week, 12-week, and 26-week follow-up time points after randomization.  However, if 
the follow-up visit cannot be performed within the one week before or after the due date for each follow-up visit 
(e.g. if a participant is sick and unable to return to the center for testing within the follow-up window), we will 
obtain follow-up measures at any point up until the next scheduled follow-up test. For example, if we are 
unable to obtain the 12-week follow-up measures within the window, we will attempt to obtain the measures 
until the 26-week follow-up testing window begins. 
D.  HUMAN SUBJECTS.
D1.  Risks to the subjects.  As described in section C.2 above, subjects will be randomized to one of four 
groups:  Group A: GM-CSF and supervised treadmill exercise; Group B: GM-CSF and attention control 
condition; Group C: placebo injections and supervised treadmill exercise; Group D: placebo injections and 
attention control condition (see Figure 2).  Study participation will last for 6 months.  Participants receiving GM-
CSF will receive a GM-CSF injection three times weekly for the first two weeks after randomization.  
Participants receiving placebo injections (rather than GM-CSF) will receive a placebo injection three times 
weekly for two weeks.  Participants randomized to supervised treadmill exercise will exercise three times 
weekly for six months with a trainer at the study exercise facility.  Participants randomized to the attention 
control group will attend weekly educational sessions at Northwestern University Feinberg School of Medicine 
for six months.  We will randomize a total of 267 participants with peripheral arterial disease (PAD).  Based on 
our prior work, we expect that 240 participants will complete the study.  Based on our previous work involving 
participants with PAD, we anticipate that the average age will be approximately 70 years, that at least 33% of 
participants will be minorities, and that approximately 50% will be women.  For example, in our recently 
completed SILC randomized controlled clinical trial of exercise in patients with PAD (see section A7 above) 
(44), participants were average age 70.6 + 10.3 and the average ABI was 0.61 + 0.17.  In SILC, participants 
included 52% women and 45% African-Americans.  In general, patients with PAD have a relatively high 
prevalence of comorbid diseases, particularly coronary artery disease, cerebrovascular disease, diabetes 
mellitus, and pulmonary disease.  Thus the patient population is likely to be of generally poorer health than that 
of similarly aged men and women without PAD in the general population.  However, subjects must be willing to 
travel to the medical center three times weekly in order to participate.  This requirement will necessarily 
eliminate some potential participants who are more frail.  Inclusion and exclusion criteria are provided in 
sections C.3 and C.4 above.  Vulnerable populations (fetuses, pregnant women, children, prisoners, and 
institutionalized persons) will not be included in this study.
Sources of material.  Primary and secondary outcome measures that will be collected for this study are 
shown in Table 6 and include the six-minute walk test, treadmill walking performance, progenitor cell 
measures, and brachial artery flow-mediated dilation (FMD).  We will also administer questionnaires to 
participants at baseline and at each follow-up visit to assess their medical history, including presence of 
comorbidities, medication use, smoking status, and other health characteristics.  Data collection will not make 
use of existing records or data.  The prevalence of comorbid disease will be measured based on patient report, 
based on previous study (91-95) (see section C.15 above).  
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
18
Potential risks.  GM-CSF is an FDA-approved medication, available commercially.  GM-CSF is produced 
using recombinant DNA technology.  Side effects of GM-CSF include myalgias, arthralgias, fever, fatigue, and 
headache (99, 100, 101).  Splenic enlargement, usually subclinical, can occur.  Splenic rupture related to GM-
CSF therapy is rare (100).  Additional rare but serious side effects, such as allergy or thrombotic events have 
also been observed (101).   
The exercise program might be associated with an increased risk of heart attack, arrhythmia, or death.  In 
addition, patients may develop ischemic chest pains during exercise.  If participants develop chest pain during 
exercise, Dr. McDermott, Dr. Lloyd-Jones, or Dr. Losordo will be notified immediately.  Dr. McDermott will 
oversee arrangement of appropriate follow-up (including immediate transport to the emergency room if 
appropriate).  The exercise physiologist is certified in Cardiopulmonary Resuscitation (CPR) and use of an 
Automatic External Defibrillator (AED).  Safety manuals and protocols will be developed prior to beginning the 
intervention.  Chest pain symptoms during exercise may result in additional cardiac work-up that may lead to 
procedures to improve coronary blood flow.  Subjects will be screened for active heart problems with a 
baseline exercise treadmill test prior to enrollment, according to currently recommended standards of 
screening PAD patients for coronary artery disease prior to their beginning an exercise program (35).  These 
exercise stress tests will be performed as part of our protocol and interpreted by board-certified cardiologist 
and co-investigator Dr. Lloyd-Jones.  Participants must have a normal 12-lead exercise stress test to be 
eligible.  Abnormal baseline exercise stress tests may lead to additional cardiac work-up by the participant’s 
physician that may lead to coronary angiography or coronary revascularization.  If the baseline exercise stress 
test is equivocal or abnormal, the participant must demonstrate evidence of a recent (within the past six 
months) normal coronary perfusion test or coronary angiogram in order to be eligible for participation.  The 
latter tests would be ordered by the participant’s physician at their discretion.  
Exercise may also be associated with muscle fatigue or soreness or dehydration which can result in fainting.  
This typically resolves with rest.  The risks associated with baseline and follow-up testing include discomfort or 
pain in the extremities during the ankle brachial index  test and falling during the walking tests.  The ankle 
brachial index will be aborted if a participant experiences severe pain during the testing.  The research 
assistant collecting these data has been trained to prevent falling.  The risk of falling is less than 1 in 200.  
Falling during these tests may be associated with fracture.  The risk of a fracture secondary to a fall during the 
walking tests is less than 1 in 5,000.   
 
D2.  Adequacy of protection against risk.  Recruitment methods are described in section C5 above.  
Informed consent will be obtained at the time of the initial study visit.  Subjects will be asked to read and sign 
the study consent form.  A research assistant will administer the consent form and answer questions.  The 
research staff has undergone human subjects training required by our institutional review board.  This training 
includes information about the importance of maintaining confidentiality of personal health information.  The 
study principal investigator or a co-investigator will be available to answer any questions as needed.  Both the 
subjects and the individual administering the consent form will sign the consent form.  
Methods to minimize potential risks.  Minimizing risks related to GM-CSF.  The GM-CSF dose to be 
administered is an FDA-approved dose with demonstrated safety in participants with PAD (1).  GM-CSF will be 
administered in our clinical research unit (CRU) by a registered nurse, who has experience administering GM-
CSF, or a physician.  Participants will be monitored in the CRU and during their return visits for side effects 
related to GM-CSF.  Specifically, the blood pressure, temperature, and heart rate of each participant will be 
obtained before and after each injection of the study drug (GM-CSF) or placebo. Following the first injection, 
participants will be monitored for 2 hours, with blood pressure and pulse obtained every 15 minutes. If a 
participant is randomized to the treadmill exercise intervention, the participant will not attend the treadmill 
exercise session on the date of the first injection. Following injections 2 through 6, the participant will be 
monitored for 20 minutes. Participants will be educated about side effects to watch for and will be asked to 
contact Dr. McDermott promptly should any significant side effects develop.  Dr. McDermott’s pager and home 
telephone number will be provided to study participants. In addition, guidelines for dose reduction have been 
developed. For example, the dose of the study drug may be decreased by study investigator Dr. David Green 
or another un-blinded study physician based on the results of the white blood count.
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
19
Minimizing risks related to exercise.  According to current clinical practice guidelines (35), all participants will 
undergo baseline exercise stress testing prior to randomization into one of the study groups.  Potential 
participants with an abnormal baseline exercise stress test will be excluded.  A physical examination will be 
completed by a physician during baseline assessments to help ensure that study participation is safe.  In 
addition, participants will be monitored during exercise for development of chest discomfort, new dyspnea, or 
new fatigue during exertion.  Dr. McDermott will be promptly notified when this occurs (by pager).  Our exercise 
physiologists have significant experience working with populations of participants with peripheral arterial 
disease and have been trained in CPR, ACLS, and use of the automatic external defibrillator.
Minimizing risk related to baseline and follow-up testing.  All study coordinators undergo baseline training and 
are certified by Dr. McDermott before beginning data collection.  Training and certification involves ensuring 
that coordinators are trained in methods to help minimize falls.  Dr. McDermott re-certifies coordinators every 
six months to ensure continued adherence to study protocol.  Those who are not adhering to protocol undergo 
additional training followed by re-certification.    
Minimizing risk related to loss of confidentiality.  A number of methods will be employed to maintain 
confidentiality of participants.  First, study recruitment letters will be mailed, using IRB-approved methods, only 
after receiving written permission from the participant’s physician.  The personal physician of each study 
participant will have the option of not allowing investigators to contact the potential participant.  Lists of 
potentially eligible participants will be obtained by individuals who normally have access to these lists as part of 
their daily work requirements.  Recruitment letters for potential participants identified from hospital and 
outpatient lists are prepared by research staff members whose job is to assist study investigators with 
recruitment.  These research staff members have completed training in the ethical conduct of human subject 
research, including maintaining participant confidentiality.  Recruitment letters to potential participants identified 
from medical center lists are mailed in sealed envelopes and addressed to the potential participant.  All 
potential participants who receive mailed information about the study after the approval from their physician will 
have the opportunity to call a voice-mail system to ask NOT to be further contacted about this study.  
Secondly, only study investigators and key research staff will have access to the study database.  Third, 
participants will be assigned a unique study identifier.  Individual names will ultimately be removed from the 
study database and only the unique study identifier will be used to distinguish participants in the database.  
Fourth, collected data will be maintained in locked computer files and file cabinets to which only study 
investigators have access.  Collected data will be used only for research purposes.  Any published data will not 
contain any individual identifiers.
Data and Safety Monitoring Board (DSMB).  As per NHLBI guidelines, the DSMB will be appointed by the 
NHLBI.  The DSMB will meet at least every six months during the study.  They will meet to review and approve 
the protocol prior to beginning data collection.  They will decide on specific stopping criteria for the study. 
However, because of the short duration of the study and because of our secondary and exploratory aims, there 
will be no criteria for stopping due to benefit.  The biostatisticians and data manager will work closely with the 
DSMB to perform interim analyses. However, since the sample size is small and the follow-up is only six 
months, we do not plan to have any stopping criteria for beneficial effect.  Rather, we will develop stopping 
criteria only for adverse effects.  
Adverse events will be monitored continuously throughout the study and will be reported to the DSMB and IRB 
in a timely manner according to pre-specified requirements.  Adverse event rates and interim study results will 
be reviewed and discussed by the DSMB at the DSMB meetings.  At least four categories of adverse events 
will be defined:  a)  Death; b) cardiovascular events (myocardial infarction, stroke, and coronary arrhythmias) c) 
musculoskeletal outcomes (muscle soreness, foot ulcer, joint aches and pains); d) additional adverse 
symptoms and events (headache, fatigue, arthralgias, fever, allergy related to GM-CSF, splenic rupture related 
to GM-CSF).  We will also monitor all hospitalizations.  We will use a designated data collection form to record 
these events and they will be reported immediately to the Institutional Review Board and DSMB.  Note that to 
date, however, exercise programs and GM-CSF have been demonstrated to be safe in patients with PAD 
(1,35,44).
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
20
The biostatisticians and data manager will work closely with the DSMB to perform interim analyses. However, 
since the sample size is small and the follow-up is only six months, we do not plan to have any stopping criteria 
for beneficial effect.  Rather, we will develop stopping criteria only for adverse effects.  For the proposed semi-
annual DSMB meetings, data will be edited and cleaned contemporaneously to data collection.  Analyses will 
be done according to the requests of the DSMB. In addition, for each major adverse event, the group 
assignment of the patient will be provided.  In this way the DSMB can determine whether the event is 
intervention related.  
D3.  Potential benefits of the proposed research.  Preliminary evidence suggests that increasing circulating 
levels of CD34+ cells with granulocyte monocyte colony stimulating factor (GM-CSF) or other therapies may 
improve walking performance in patients with lower extremity peripheral arterial disease (PAD) (1,2).  
However, results of small clinical trials are mixed (1-4). The association of GM-CSF with improved walking 
performance in PAD is not definitively established.  Preliminary data also suggest that lower extremity 
ischemia, induced during walking exercise, may increase circulating CD34+ cell levels, enhance homing of 
CD34+ cells to ischemic sites, and augment the ability of GM-CSF to improve walking performance in PAD 
(1,2).  However, whether the combination of GM-CSF and supervised treadmill exercise improve walking 
performance more than GM-CSF and supervised treadmill exercise, respectively, is currently unknown. This 
proposed clinical trial is needed to definitively establish a) whether the combination of supervised treadmill 
exercise and GM-CSF improves functional performance in PAD participants with and without intermittent 
claudication more than either intervention individually; b) whether GM-CSF improves functional performance in 
PAD patients with and without intermittent claudication as compared to placebo; c) whether supervised 
treadmill exercise increases circulating levels of CD34+ cells; d) whether the degree of increase in CD34+ cells 
is associated with the degree of improvement in six-minute walk performance; e) the temporal trajectory of 
improvement in study outcomes in response to study interventions and increases in progenitor cells.  In 
addition to establishing the therapeutic benefit of GM-CSF with and without supervised treadmill exercise, this 
proposed study is expected to identify biological pathways associated with improved functional performance in 
patients with PAD.  This information is expected to lead to new therapies to improve walking performance in 
patients with PAD.  
D4.  Importance of knowledge to be gained.  Lower extremity peripheral arterial disease (PAD) is common.  
Currently 8 million men and women in the United States (U.S.) have PAD (5).  The number of individuals with 
PAD is expected to increase as the U.S. population lives to older ages with chronic disease.  Our prior work 
and that of others shows that patients with PAD have greater functional impairment, increased rates of 
functional decline, and increased mobility loss compared to persons without PAD (6-11).  Older patients with 
functional impairment are less likely to remain independent in the community, have higher rates of 
hospitalization, and have poorer quality of life than those without functional impairment (12).  Yet few therapies 
have been identified that improve lower extremity functioning or prevent functional decline or mobility loss in 
persons with PAD.  Only two FDA-approved medications improve functional performance in patients with PAD.  
Identifying biological pathways associated with improved functional performance in PAD is expected to lead to 
new therapies to help patients with PAD preserve their functional performance and avoid decline.  These 
findings will have important public health implications for preventing disability and nursing home placement for 
a large number of individuals.  
D5.  Collaborating sites.  Brachial artery flow-mediated dilation results will be interpreted by Dr. James 
Stein’s laboratory at the University of Wisconsin Medical School.  Videotapes of the brachial artery flow 
mediated dilation measurement will be mailed to Dr. Stein’s laboratory and results will be returned to 
Northwestern investigators. We have experience working with Dr. Stein in this capacity in our recently 
completed randomized controlled trial of exercise in patients with PAD (44).  Dr. Lu Tian, assistant professor in 
the Department of Biostatistics at Stanford, will assist with statistical analyses.  Dr. Tian was previously a 
faculty member at Northwestern University and has worked with Dr. McDermott, Dr. Liu, and other study 
investigators for more than five years.  Drs. Michael H. Criqui (University of California at San Diego), Jack M. 
Guralnik (National Institute on Aging), and Luigi Ferrucci (National Institute on Aging) have worked with Dr. 
McDermott on PAD studies of functional impairment for over nine years and bring expertise in functional 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
21
assessment, PAD, and clinical trials to the study team.  Drs. Brian Annex and Doris Taylor bring expertise in 
PAD, clinical trials, and/or progenitor cell measurement and interpretation to the study team. 
E.  Inclusion of Women/Minorities.  PAD is common among older women and among African-Americans 
(102).  We will ensure that our study population includes at least approximately 50% women and at least 
approximately 25% African-American (see enrollment table).  We do not anticipate difficulty achieving these 
recruitment targets, since our recently completed randomized controlled clinical trial of exercise in participants 
with PAD included 52% women and 40% minorities (44).  Our group has substantial experience successfully 
recruiting and enrolling women and minorities for our observational and clinical trial research in participants 
with PAD.
Methods to ensure adequate enrollment of women and minorities.  To ensure that we achieve a study 
population that includes approximately 50% women and at least 25% minorities, we will make study 
participation as simple and enjoyable as possible for women and minority participants.  For example, we can 
provide door-to-door transportation to study visits.  We have also advertised our research opportunities on 
radio or in newspapers for which the audience includes a high proportion of minority populations.  If we still 
have difficulty recruiting significant proportions of minorities, we will enlist minority leaders in the community to 
assist with recruitment and we will make a substantial effort to hire an African-American research assistant to 
assist us with recruitment.  
Alternatives should the above methods be insufficient.  If the above methods are not sufficient, then we 
will expand our recruitment of participants to hospitals in which the majority of patients are minorities.  For 
example, colleague and vascular surgeon Dr. Walter McCarthy is director of the non-invasive vascular 
laboratory at Cook County Hospital in Chicago.  Similarly, colleague and vascular surgeon Dr. Melina Kibbe is 
a vascular surgeon at the VA Chicago Medical Center.  If necessary, we will work with Drs. McCarthy and 
Kibbe to identify additional participants from Cook County Hospital and VA Chicago, where many patients are 
members of under-represented minority populations.F. Inclusion of Children.  PAD does not affect children.  
Therefore, children will not be included in the PROPEL study.
LITERATURE CITED
1.  Subramaniyam V, Waller EK, Murrow JR, Manatunga A, Lonial S, Kasirajan K, Sutcliffe D, Harris W, Taylor 
W, Alexander R.  Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves 
endothelial dysfunction and exercise capacity in patients with peripheral arterial disease.  Am Heart J 
2009;158:53-60.
2.  Sandri M, Adams V, Gielen S, Linke A, Lenk K, Kränkel N, Lenz D, Erbs S, Scheinert D, Mohr FW, Schuler 
G, Hambrecht R. Effects of exercise and ischemia on mobilization and functional activation of blood-derived 
progenitor cells in patients with ischemic syndromes: results of 3 randomized studies. Circulation 
2005;111:3391-3399.
3.  Van Royen N, Schirmer SH, Atasever B, Behrens CYH, Ubbink D, Buschmann EE, Voskuil M, Bot P, 
Hoefer I, Schlingemann RO, Biemond BJ, Tijssen JG, Bode C, Schaper W, Oskam J, Legemate DA, Piek JJ, 
Buschmann I.  START Trial:  A pilot study on Stimulation or ARTeriogenesis using subcutaneous application of 
granulocyte-macrophage colony stimulating factor as a new treatment for peripheral arterial disease.  
Circulation 2005;112:1040-1046. 
4.  Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K, Tsuchiya K, Otsuka S, Uno Y, Takemura 
G, Nishigaki K, Minatoguchi S, Fujiwara H.  Granulocyte colony-stimulating factor:  A noninvasive regeneration 
therapy for treating atherosclerotic peripheral arterial disease. Circ J 2006;70:1093-1098.
5.  Allison MA, Ho E, Denenberg JO, Langer RD, Newman AB, Fabsitz RR, Criqui MH. Ethnic-specific 
prevalence of peripheral arterial disease in the United States.  Am J Prev Med 2007;32:328-333.
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
22
6.  McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, Chan C, Celic L, Pearce WH, 
Schneider JR, Sharma L, Clark E, Gibson D, Martin GJ.  Leg symptoms in peripheral arterial disease.  
Associated clinical characteristics and functional impairment.  JAMA 2001;286:1599-1606.
7.  McDermott MM, Liu K, Greenland P, Guralnik JM, Criqui MH, Chan C, Pearce WH, Schneider JR, Ferrucci 
L, Celic L, Taylor LM, Vonesh E, Martin GJ, Clark E.  Functional decline in peripheral arterial disease: 
associations with the ankle brachial index and leg symptoms. JAMA 2004;292:453-461.
8.  McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, Chan C, Martin GJ, Schneider J, 
Pearce WH, Taylor LM, Clark E.  The ankle brachial index as a measure of leg functioning and physical activity 
in peripheral arterial disease: the walking and leg circulation study. Ann Intern Med 2002;136:873-883.
9.  Gardner AW, Montgomery PS. Impaired balance and higher prevalence of falls in subjects with intermittent 
claudication. J Gerontol A Biol Sci Med Sci 2001;56(7):M454-458.
10.  Gardner AW, Montgomery PS, Killewich LA. Natural history of physical function in older men with 
intermittent claudication. J Vasc Surg 2004;40(1):73-78.
11.  McDermott MM, Guralnik JM, Tian L, Ferrucci L, Liu K, Liao Y, Criqui MH. Baseline functional performance 
predicts the rate of mobility loss in persons with peripheral arterial disease. J Am Coll Cardiol 2007;50:974-
982.
12.  Fried LP, Guralnik JM.  Disability in older adults:  evidence regarding significance, etiology, and risk.  J Am 
Geriatr Soc 1997;45:92-100.
13.  McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J, Pearce WH, Schneider JR, Criqui MH. 
Prognostic value of functional performance for mortality in patients with peripheral artery disease.  JACC 
2008;51:1482-1489.  PMID: 18402904
14.  Dawson DL, Cutler BS, Meissner MH, Strandness DEJ.  Cilostazol has beneficial effects in treatment of 
intermittent claudication:  Results from a multi-center, randomized, prospective, double-blind trial.  Circulation 
1998;98:678-686.
15.  Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J, Forbes WP. Effect of cilostazol on 
walking distances in patients with intermittent claudication caused by peripheral vascular disease.  J Vasc Surg 
1998;27:267-274.
16.  Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, Forbes WP. A new 
pharmacological treatment for intermittent claudication:  results of a randomized, multi-center trial.  Arch Intern 
Med 1999;159:2041-2050. 
17.  Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, Prandoni P, Girolami A, Buller HR.  
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl:  A 
meta-analysis.   Arch Intern Med 1999;159:337-345.
18.  Ben Shoshan J and George J.  Endothelial progenitor cells as therapeutic vector in cardiovascular 
disorders:  From Experimental models to human trials.  Pharmacology and Therapeutics 2007:25-36. 
19.  Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. 
Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for 
neovascularization. Nat Med 1999; 5:434–438.
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
23
20.  Takazoe M, Matsui T, Motoya S, Matsumoto T, Hibi T, Watanabe M.  Sargramostim in patients with 
Crohn’s disease:  Results of a phase 1-2 study.  J Gastroenterol 2009;44:535-543.
21.  Laufs U, Werner N, Link A, Endres M, Wassmann S, Jürgens K, Miche E, Böhm M, Nichenig G.  Physical 
Training Increases Endothelial Progenitor Cells, Inhibits Neointima Formation, and Enhances Angiogenesis. 
Circulation 2004;109:220-226.
22.  Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner 
JM. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. Science 1997;275:964-967.
23.  Murasawa S, Asahara T. Cardiogenic potential of endothelial progenitor cells.  Ther Adv Cardiovasc Dis 
2008 Oct;2(5):341-348.
24.  Thijssen DHJ, Torella D, Hopman MTE, Ellison GM. The role of endothelial progenitor and cardiac stem 
cells in the cardiovascular adaptations to age and exercise. Frontiers in Bioscience 2009;14:4685-4702.
25.  Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T.  Circulating endothelial 
progenitor cells, vascular function, and cardiovascular risk.  N Engl J Med 2003;348:593-600.
26.  Taylor DA, Zenovich AG.  Cardiovascular cell therapy and endogenous repair.  Diabetes Obes Metab 
2008 Nov;10 Suppl 4:5-15.
27.  Zenovich AG, Taylor DA.  Atherosclerosis as a disease of failed endogenous repair.  Front Biosci 2008 
May 1;13:3621-3636. Review
28.  Alobaid N, Alnaeb ME, Sales KM, Seifalian AM, Mikhailidis DP, Hamilton G.  Endothelial progenitor cells 
and their potential clinical applications in peripheral arterial disease.  Endothelium 2005 Sep-Dec;12(5-6):243-
250.
29.  Li B, Sharpe EE, Maupin AB, Teleron AA, Pyle AL, Carmeliet P, Young PP. VEGF and PIGF promote 
adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor 
neovascularization.  FASEB J 2006;20:1495-1497.
30.  Murohara T, Ikeda H, Duan J, Shintani S, Sasaki K, Eguchi H, Onitsuka I, Matsui K, Imaizumi T. 
Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin 
Invest 2000;105(11):1527-1536.
31. Devanesan AJ, Laughlan KA, Girn HRS, Homer-Vanniaskinkam S.  Endothelial progenitor cells as a 
therapeutic option in peripheral arterial disease.  Eur J Vasc Endovasc Surg 2009;38:475-481. 
32.  Ishida A, Ohya Y, Sakuda H, Ohshiro K, Higashiuesato Y, Nakaema M, Matsurbara S, Yakabi S, Kakihana 
A, Ueda M, Miyagi C, Yamane N, Koja K, Komori K, Takishita S.  Autologous peripheral blood mononuclear 
cell implantation for patients with peripheral arterial disease improves limb ischemia.  Circ J 2005;69:1260-
1265.
33.  Kovacic JC, Muller DWM, Graham RM.  Actions and therapeutic potential of G-CSF and GM-CSF in 
cardiovascular disease.  Journal of molecular and cellular cardiology;2007:19-33.
34.  Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, 
Hunninghake DB, Comerota AH, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, 
awareness, and treatment in primary care. JAMA 2001;286(11):1317-1324.
35.  Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin 
JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
24
EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura 
R, Ornato JP, Page RL, Riegel B; American Association for Vascular Surgery/Society for Vascular Surgery; 
Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society 
of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines. ACC/AHA Guidelines for the 
Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal 
aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular 
Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, 
Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to 
develop guidelines for the management of patients with peripheral arterial disease)--summary of 
recommendations. J Vasc Interv Radiol 2006;17:1383-1397. 
36.  Regensteiner JG.  Exercise rehabilitation for the patient with intermittent claudication: a highly effective yet 
underutilized treatment. Curr Drug Targets Cardiovasc Haematol Disord 2004;4:233-239.
37.  Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, 
Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of 
SDF-1. Nat Med 2004;10:858–864.
38.  Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, Bernasconi S, Saccani S, 
Nebuloni M, Vago L, Mantovani A, Melillo G, Sica A. Regulation of the chemokine receptor CXCR4 by hypoxia. 
J Exp Med 2003;198:1391–1402.
39.  Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Takayuki A. 
Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for 
neovascularization. Nat Med 1999; 5:434–438.
40.  Misao Y, Takemura G, Arai M, Ohno T, Onogi H, Takahashi T, Minatoguchi S, Fujiwara T, Fujiwara H.  
Importance of recruitment of bone marrow-derived CXCR4(+) cells in post-infarct cardiac repair mediated by 
G-CSF.  Cardiovasc Res 2006;71:455-465.
41.  Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1alpha plays a 
critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing
in the absence of injury. Circulation 2004;110:3300–3305.
42.  Butler JM, Guthrie SM, Koc M, Afzal A, Caballero S, Brooks HL, Mames RN, Segal MS, Grant MB, Scott 
EW. SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest 2005;115:86–93.
43.  De Falco E, Porcelli D, Torella AR, Straino S, Iachininoto MG, Orlandi A, Truffa S, Biglioli P, Napolitano M, 
Capogrossi MC, Pesce M. SDF-1 involvement in endothelial phenotype and ischemia induced recruitment of 
bone marrow progenitor cells. Blood 2004;104:3472–3482.
44.  McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, Nelson M, Lloyd-Jones D, Van Horn L, 
Garside D, Kibbe M, Domanchuk K, Stein JH, Liao Y, Tao H, Green D, Pearce WH, Schneider JR, McPherson 
D, Laing ST, McCarthy WJ, Shroff A, Criqui MH. Treadmill exercise and resistance training in patients with 
peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 
2009;301(2):165-174.  PMID: 19141764
45.  Steiner S, Niessner A, Ziegler S, Richter B, Seidinger D, Pleiner J, Penka M, Wolzt M, Huber K, Wojta J, 
Minar E, Kopp CW. Endurance training increases the number of endothelial progenitor cells in patients with 
cardiovascular risk and coronary artery disease. Atherosclerosis 2005;181: 305–310.
46.  Paul JD, Powell TM, Thompson M, Benjamin M, Rodrigo M, Carlow A, Annavajjhala V, Shiva S, Dejam A, 
Gladwin MT, McCoy JP, Zalos G, Press B, Murphy M, Hill JM, Csako G, Waclawiw MA, Cannon RO 3rd. 
Endothelial progenitor cell mobilization and increased intravascular nitric oxide in patients undergoing cardiac 
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
25
rehabilitation. J Cardiopulm Rehabil Prev 2007;27:65-73.
47.  Thijssen DH, Vos JB, Verseyden C, van Zonneveld AJ, Smits P, Sweep FC, Hopman MT, de Boer HC. 
Haematopoietic stem cells and endothelial progenitor cells in healthy men: effect of aging and training. Aging 
Cell 2006;5:495-503.
48.  Cesari F, Sofi F, Caporale R, Capalbo A, Marcucci R, Macchi C, Lova RM, Cellai T, Vannucci M, Gensini 
GF, Abbate R, Gori AM. Relationship between exercise capacity, endothelial progenitor cells and 
cytochemokines in patients undergoing cardiac rehabilitation. Thromb Haemost 2009;101:521-526.
49. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo 
A, Agostini C, Avogaro A. Circulating endothelial progenitor cells are reduced in peripheral vascular 
complications of Type 2 Diabetes Mellitus.  J Am Coll Cardiol 2005;45:1449-1457.
50. Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F, Vigili de Kreutzenberg S, 
Tiengo A, Agostini C, Avogaro A. Number and function of endothelial progenitor cells as a marker of severity 
for diabetic vasculopathy.  Arterioscler Thromb Vasc BIol 2006;26:2140-2146.
51.  McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian L, Liao Y, Criqui MH.  Leg Symptom Categories and 
Rates of Mobility Decline in Peripheral Arterial Disease.  J Am Geriatr Soc (In Press).
52. Greig C, Butler F, Skelton D, Mahmud S, Young A. Treadmill walking in old age may not reproduce the real 
life situation. J Am Geriatr Soc 1993;41:15-18.
53.  Swerts PMJ, Mostert R, Wouters EFM.  Comparison of corridor and treadmill walking in patients with 
severe chronic obstructive pulmonary disease.  Phys Ther 1990;70:439-442.
54.  Peeters P, Mets T.  The six-minute walk as an appropriate exercise test in elderly patients with chronic 
heart failure.  J Gerontol Med Sci 1996;51A:M147-M151
55.  McDermott MM, Guralnik JM, Tian L:, Ferrucci L, Liao Y, Sharma L, Criqui MH.  Associations of borderline 
and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking 
and Leg Circulation Study).  J Am Coll Cardiol 2009;53:1063-1064.  PMID: 19298919
56.  McDermott MM, Guralnik JM, Ferrucci L, Tian L, Liu K, Liao Y, Green D, Sufit R, Hoff F, Nishida T, 
Sharma L, Pearce WH.  Asymptomatic peripheral arterial disease is associated with more adverse lower 
extremity characteristics than intermittent claudication. Circulation 2008;117:2484-2491.  PMID: 18458172
57.  McDermott MM, Fried L, Simonsick E, Ling S, Guralnik JM.  Asymptomatic peripheral arterial disease is 
independently associated with impaired lower extremity functioning: the women’s health and aging study.  
Circulation 2000;101:1007-1012.
58.  McDermott MM, Domanchuk K, Dyer A, Ades P, Kibbe M, Criqui MH. Recruiting participants with 
peripheral arterial disease for clinical trials: Experience from the study to improve leg circulation (SILC). J Vasc 
Surg 2009;49:653-659.  PMID: 19135834
60.  Lijmer JG, Hunink MG, van den Dungen JJ, Loonstra J, Smit AJ.  ROC analysis of noninvasive tests for 
peripheral arterial disease.  Ultrasound Med Biol 1996;22:391-398. 
61.  Bernstein EF, Fronek A.  Current status of non-invasive tests in the diagnosis of peripheral arterial 
disease.  Surg Clin North Am 1982;62:473-487.
62. Fung YC.  Blood flow in arteries: pressure and velocity waves in large arteries and the effects of geometric 
nonuniformity. In Biodynamics – Circulation New York: Springer-Verlag, 1984:133-136.
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
26
63.  Yao JS. New techniques of objective arterial evaluation.  Arch Surg 1973;106:600-604.
64.  Huen R, Papassotiropoulos A, Jennssen F.  The validity of psychometric instruments for detection of 
dementia in the elderly general population.  Int J Geriatr Psychiatry 1998;13:368-380.
65.  Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A 
meta-analysis. JAMA 1995;274:975-980.
66.  Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med 
2002;347:1941-1951.
67.  Bendermacher BL, Willigendael EM, Teijink JA, Prins MH.  Supervised exercise therapy versus non-
supervised exercise therapy for intermittent claudication.  Cochrane Database Syst Rev 2006;2:CD005263.
68.  Murasawa S, Asahara T. Cardiogenic potential of endothelial progenitor cells.  Ther Adv Cardiovasc Dis 
2008 Oct;2(5):341-348.
69.  Thijssen DHJ, Torella D, Hopman MTE, Ellison GM. The role of endothelial progenitor and cardiac stem 
cells in the cardiovascular adaptations to age and exercise. Frontiers in Bioscience 2009;14:4685-4702.
70.  Borg GV.  Psychophysical bases of perceived exertion.  Med Sci Sports Exerc 1982;14:377-381.
71.  Dunbar CC, Goris C, Michielli DW, Kalinski MI.  Accuracy and reproducibility of an exercise prescription 
based on Ratings of Perceived Exertion for treadmill and cycle ergometer exercise.  Perceptual & Motor Skills 
Jun 1994;78(3Pt2): 1335-1344.
72.  Eston RG, Williams JG.  Reliability of ratings of perceived effort regulation of exercise intensity.  British J 
of Sports Med Dec 1988;22(4):153-155.
73. Feriche B, Chicharro JL, Vaquero AF, Perez M, Lucia A.  The use of a fixed value of RPE during a ramp 
protocol.  Comparison with the ventilatory threshold.  J Sports Med & Physical Fitness Mar 1998;38(1): 35-38. 
74.  Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, 
Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo 
G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC.  2006 Update of recommendations for use of white 
blood cell growth factors:  An evidence-based clinical practice guideline.  Journal of Clinical Oncology 
2006;24:3187-3205.
75.  Takazoe M, Matsui T, Motoya S, Matsumoto T, Hibi T, Watanabe M.  Sargramostim in patients with 
Crohn’s disease:  Results of a phase 1-2 study.  J Gastroenterol 2009;44:535-543.
76.  Kawamoto A, Katayama M, Handa N, Kinoshita M, Takano H, Horii M, Sadamoto K, Yokoyama A, 
Yamanaka T, Onodera R, Kuroda A, Baba R, Kaneko Y, Tsukie T, Kurimoto Y, Okada Y, Kihara Y, Morioka S, 
Fukushima M, Asahara T.  Intramuscular transplantation of G-CSF-Mobilized CD34+ cells in patients with 
critical limb ischemia:  A Phase I/IIa, Multicenter, Single-blinded, dose-escalation clinical trial.  Stem Cells 
2009;27:2857-2864.
77.  Tateishi-Yuyama E, Matsubara H, Murohara T and the Therapeutic Angiogenesis using Cell 
Transplantation (TACT) Study Investigators.  Therapeutic angiogenesis for patients with limb ischemia by 
autologous transplantation of bone-marrow cells:  A pilot study and a randomized controlled trial.  Lancet 
2002;360:427-435.
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
27
78.  Chen SL, Fang WW, Quian J,Ye F, Liu YH, Shan SJ, Zhang JJ, Lin S, Liao LM, Zhao RC. Improvement of 
cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with 
acute myocardial infarction.  Chin Med J 2004;117:1443-1448.
79.  Kueth F, Richartz BM, Kasper C, Sayer HG, Hoeffken K, Werner GS, Figulla HR.  Autologous 
intracoronary mononuclear bone marrow cell transplantation in chronic ischemic cardiomyopathy in humans.  
Int J Cardiol 2005;100:485-491.
80.  Pasquet S, Sovalat H, Henon P, Bischoff N, Arkam Y, Ojeda-Uribe M, Bouar R, Rimelen V, Brink I, 
Dallemand R, Monassier JP.  Long-term benefit of intracardiac delivery of autologous granulocyte-colony-
stimulating factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and 
function after myocardial infarct.  Cytotherapy 2009;11:1002-1015.  
81.  McDermott MM, Ades PA, dyer A, Gurlanik JM, Kibbe M, Criqui MH.  Corridor-based functional 
performance measures correlate better with physical activity during daily life than treadmill measures in 
persons with peripheral arterial disease.  J Vasc Surg 2008;48:1231-1237.  PMID: 18829215
82.  Gardner AW, Skinner JS, Cantwell BW, Smith LK.  Progressive vs. single-stage treadmill tests for 
evaluation of claudication.  Med Sci Sports Exerc 1991;23:402-408.
83.  Gardner AW, Skinner JS, Cantwell BW, Smith LK.  Effects of handrail support on claudication and 
hemodynamic responses to single-stage and progressive treadmill protocols in peripheral vascular occlusive 
disease.  Am J Cardiol 1991;67:99-105.     
84. Hiatt WR, Regensteiner JG, Hargarten ME, Wolfel EE, Brass EP.  Benefit of exercise conditioning for 
patients with peripheral arterial disease.  Circulation 1990;81:602-609.
85.  Montgomery PS, Gardner AW. The clinical utility of a six-minute walk test in peripheral arterial occlusive 
disease patients.  J Am Geriatr Soc 1998;46:706-711.
86.  Payvandi L, Dyer A, McPherson D, Ades P, Stein J, Liu K, Ferrucci L, Criqui MH, Guralnik JM, Lloyd-
Jones D, Kibbe MR, Liang ST, Kane B, Pearce WH, Verta M, McCarthy MJ, Schneider JR, Shroff A, 
McDermott MM. Physical activity during daily life and brachial artery flow-mediated dilation in peripheral arterial 
disease.  2009:14:193-201.  
87.  Yeboah J, Folsom AR, Burke GL, Johnson c, Polak JF, Post W, Lima JA, Crouse JR, Herrington DM.  
Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based 
study: the multi-ethnic study of atherosclerosis. Circulation 2009;120:502-509.  
88.  Gottdiener JS, Bednarz J, Devereux RM, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, 
Quinones M, Schiller NB, Stein JH, Weissman NJ; American Society of Echocardiography. American Society 
of  Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 
2004;17:1086-1119.
89. Zeiher AM, Krause T, Schachinger V, Minners J, Moser E.  Impaired endothelium-dependent vasodilation 
of coronary resistance vessels is associated with exercise-induced myocardial ischemia.  Circulation 1995 
91(9):2345-2352.
90.  Zeiher AM, Schachinger V, Minners J.  Long-term cigarette smoking impairs endothelium-dependent 
coronary arterial vasodilator function.  Circulation 1995;92(5):1094-1100. 
91.   Ferraro KJ, Su YP.  Physician-evaluated and self-reported morbidity for predicting disability.  J Clin 
Epidemiol 1996;49:989-995.
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.


Version 3.13.2017
28
92.  Fowles JB, Fowler EJ, Craft C.  Validation of claims diagnoses and self-reported conditions compared with 
medical records for selected chronic diseases.  J Ambulatory Care Manage 1998;21:24-34.
93.  Ferraro KF, Yaping S.  Physician-evaluated and self-reported morbidity for predicting disability.  Am J 
Public Health 2000;90:103-108.
94.  Roberts RO, Bergstralh EJ, Schmidt L, Jacobsen SJ.  Comparison of self-reported and medical record 
health care utilization measures.  J Clin Epidemiol 1996;49:989-995.
95.  Bergmann MM, Byers T, Freedman DS, Mokdad A.  Validity of self-reported diagnoses leading to 
hospitalization:  A comparison of self-reports with hospital records in a prospective study of American adults.  
Am J Epidemiol 1998;147:969-977.
96.  Wagenknecht LE, Burke GL, Perkins LL, Haley NJ, Friedman GD.  Misclassification of smoking status in 
the CARDIA study:  A comparison of self-report with serum cotinine levels.  Am J Public Health 1992;82:33-36.
96.  Zhang M, Anastasios A, Tsiatis, Davidian M.  Improving efficiency of inferences in randomized clinical 
trials using auxiliary covariates, Biometrics 2008;64:707-715.
97.  Vidula H, Tian L, Liu K, Criqui MH, Ferrucci L, Pearce WH, Greenland P, Green D, Tan J, GarsideDB, 
Guralnik J, Ridker PM, Rifai N, McDermott MM.  Biomarkers of inflammation and thrombosis as predictors of 
near-term mortality in patients with peripheral arterial disease: a cohort study.  Ann Intern Med 2008;148:85-
93.
98.  McDermott MM, Liu K, Ferrucci L, Criqui MH, Greenland P, Guralnik JM, Tian L, Schneider JR, Pearce 
WH, Tan J, Martin GJ.  Physical performance in peripheral arterial disease: a slower rate of decline in patients 
who walk more.  Ann Intern Med 2006;144:10-20.  
99.  Anderlini P, Przepiorka D, Champlin R, Korbling M.  Biologic and clinical effects of granulocyte colony-
stimulating factor in normal individuals.  Blood 1996;88:2819-2825.
100.  Dincer AP, Gottschall J, Margolis DA.  Splenic rupture in a parental donor undergoing peripheral blood 
progenitor cell mobilization.  J Pediatr Hematol Oncol 2004;26:761-763.
101.  Kovacic JC, Macdonald P, Freund J, Rasko JE, Allan R, Fernandes VB, Ma D, Moore J, Graham RM.  
Profound thrombocytopenia related to G-CSF.  Am J Hematol 2007;82:229-230.
102.  McDermott MM, Liu K, Criqui MH, Ruth K, Goff D, Saad MF, Wu C, Homma S, Sharrett AR.  Ankle-
brachial index and subclinical cardiac and carotid disease:  the multi-ethnic study of atherosclerosis.  Am J 
Epidemiol 2005;162:33-41.
IRB #: STU00049675 Approved by NU IRB for use on or after 2/19/2018 through 2/18/2019.